CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11695249,116952495,5,F,20090930,20190128,20151103,20190205,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-009507513-0906USA00645,MERCK,,19,YR,,F,Y,,,20190205,,MD,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,116952495,OT,,,116952495,1,20080215,,,,116952495,1,HIV infection
11883063,118830637,7,F,,20190227,20151231,20190313,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-090408,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20190313,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,118830637,OT,,,118830637,1,2007,,,,118830637,1,HIV infection
11991033,119910334,4,F,,20190312,20160202,20190322,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190322,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,119910334,OT,,,,,,,,,119910334,1,Product used for unknown indication
12161166,121611664,4,F,,20190108,20160308,20190122,EXP,,CA-ABBVIE-10P-163-0641882-00,ABBVIE,"PFEFFER G, COTE H, MONTANER J, ET AL. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009 JUL;73:71-72.",52,YR,,M,Y,,,20190122,,MD,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,121611664,OT,,,121611664,1,200802,200802,,,121611664,1,HIV infection
12487439,124874393,3,F,,20190227,20160622,20190311,EXP,UG-MLMSERVICE-20170907-0858234-3,UG-CIPLA LTD.-2016UG07222,CIPLA,"SEKAGGYA C, NALWANGA D, VON BRAUN A, NAKIJOBA R, KAMBUGU A, FEHR J ET AL.. CHALLENGES IN ACHIEVING A TARGET INTERNATIONAL NORMALIZED RATIO FOR DEEP VEIN THROMBOSIS AMONG HIV-INFECTED PATIENTS WITH TUBERCULOSIS: A CASE SERIES. BMC HEMATOLOGY. 2016;16 (16):1 TO 5",,,,,Y,,,20190311,,OT,UG,UG,EFAVIRENZ.,Drug interaction,,,,,,,,,,,124874393,1,HIV infection
12643972,126439725,5,F,,20190213,20160811,20190225,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK112581,VIIV,,51,YR,,M,Y,,,20190225,,OT,IL,IL,EFAVIRENZ.,Aspartate aminotransferase increased;Blood lactate dehydrogenase increased;Cardiac failure;Coronary artery stenosis;Dyspnoea;Ischaemic stroke;Myocarditis;Oedema peripheral;Sleep disorder;Troponin T increased;Ventricular dysfunction,126439725,OT,,,,,,,,,126439725,1,HIV infection
12855273,128552734,4,F,20161003,20190116,20161017,20190123,EXP,,MW-GILEAD-2016-0237668,GILEAD,,25,YR,A,M,Y,,,20190123,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,128552734,OT,,,128552734,1,20160818,20161003,,,128552734,1,Kaposi's sarcoma AIDS related
13105691,131056913,3,F,,20190213,20170111,20190225,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2016GSK195660,VIIV,"MAHLAB-GURI K, ASHER I, ROSENBERG-BEZALEL S, ELBIRT D, BURKE M, STHOEGER ZM. TWO CASE REPORTS OF SEVERE MYOCARDITIS ASSOCIATED WITH THE INITIATION OF DOLUTEGRAVIR TREATMENT IN HIV PATIENTS. MEDICINE (UNITED STATES). 2016;95(47)",51,YR,,M,Y,,,20190225,,MD,IL,IL,EFAVIRENZ.,Cardiac failure;Dyspnoea;Dyspnoea exertional;Myocardial infarction;Myocarditis;Oedema peripheral;Sleep disorder;Ventricular dysfunction,131056913,OT,,,,,,,,,131056913,1,HIV infection
13274215,132742157,7,F,,20190215,20170227,20190226,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-015407,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,,,20190226,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132742157,OT,,,132742157,1,200909,,,,132742157,1,HIV infection
13278460,132784609,9,F,,20190218,20170228,20190225,EXP,,FR-009507513-1702FRA008506,MERCK,"RUELLAN AL, VEYRAC G, BRUNET-CARTIER C, JARNET L, JOLLIET P.. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30(SUPPL 1):50",32,YR,,F,Y,,,20190225,,OT,FR,FR,EFAVIRENZ.,Abortion induced;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue,132784609,OT,,,132784609,1,201007,,,,132784609,1,Contraception
13565295,135652952,2,F,,20170515,20170519,20190305,EXP,,ZA-MYLANLABS-2017M1029650,MYLAN,,,,I,F,Y,,,20190305,,CN,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Corneal opacity congenital;Foetal exposure during pregnancy,135652952,CA,,,,,,,,,135652952,1,HIV infection
13925619,139256193,3,F,,20190227,20170831,20190304,EXP,,UG-SA-2017SA157037,SANOFI AVENTIS,,40,YR,A,F,Y,,,20190304,,OT,UG,UG,EFAVIRENZ.,Anticoagulation drug level above therapeutic;Drug interaction;Epistaxis,139256193,OT,,,,,,,,,139256193,2,HIV infection
14123977,141239773,3,F,,20190125,20171025,20190208,EXP,,FR-AUROBINDO-AUR-APL-2017-42195,AUROBINDO,,37,YR,,F,Y,,,20190208,,MD,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,141239773,HO,,,141239773,5,20150608,20150608,,,141239773,1,HIV infection
14246609,142466097,7,F,,20190201,20171204,20190205,EXP,,GB-AUROBINDO-AUR-APL-2017-43959,AUROBINDO,,85,YR,,M,Y,,,20190205,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,142466097,OT,,,,,,,,,142466097,1,Cardiovascular event prophylaxis
14306973,143069734,4,F,,20190228,20171220,20190312,EXP,,CA-APOTEX-2017AP022582,APOTEX,,54,YR,,M,Y,,,20190312,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,143069734,OT,,,,,,,,,143069734,1,Bipolar disorder
14318289,143182893,3,F,,20190201,20171222,20190205,EXP,,GB-AUROBINDO-AUR-APL-2017-46472,AUROBINDO,,85,YR,,M,Y,,,20190205,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143182893,OT,,,,,,,,,143182893,1,Cardiovascular event prophylaxis
14318341,143183412,2,F,,20190128,20171222,20190208,EXP,,GB-AUROBINDO-AUR-APL-2017-46773,AUROBINDO,,,,,,Y,,,20190208,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143183412,OT,,,,,,,,,143183412,1,Cardiovascular event prophylaxis
14345648,143456483,3,F,,20190128,20180103,20190208,EXP,,GB-AUROBINDO-AUR-APL-2017-48622,AUROBINDO,,,,,,Y,,,20190208,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143456483,OT,,,,,,,,,143456483,1,Cardiovascular event prophylaxis
14352961,143529613,3,F,20150608,20190118,20180104,20190128,EXP,,FR-MYLANLABS-2018M1000485,MYLAN,,,,,M,Y,2.64,KG,20190128,,CN,US,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,143529613,OT,,,143529613,5,20150608,20150608,,,143529613,1,HIV infection
14355025,143550256,6,F,,20190128,20180105,20190208,EXP,,GB-AUROBINDO-AUR-APL-2018-000089,AUROBINDO,,85,YR,,M,Y,,,20190208,,CN,GB,GB,EFAVIRENZ.,Drug interaction;Renal impairment,143550256,OT,,,,,,,,,143550256,1,Cardiovascular event prophylaxis
14457277,144572772,2,F,,20190205,20180130,20190215,EXP,,GB-AUROBINDO-AUR-APL-2018-004041,AUROBINDO,,,,,,Y,,,20190215,,CN,GB,GB,EFAVIRENZ.,Lip and/or oral cavity cancer,144572772,OT,,,,,,,,,144572772,1,Antiretroviral therapy
14494652,144946522,2,F,,20180123,20180206,20190322,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-006996,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20190322,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,144946522,OT,,,,,,,,,144946522,1,HIV infection
14596238,145962386,6,F,,20190214,20180303,20190227,EXP,,FR-AUROBINDO-AUR-APL-2018-010672,AUROBINDO,,,,,,Y,,,20190227,,OT,US,FR,Efavirenz Film Coated Tablets,Abortion induced;Drug interaction;Labelled drug-drug interaction medication error;Maternal exposure during pregnancy;Pregnancy with implant contraceptive;Product use issue;Unwanted pregnancy,145962386,OT,,,145962386,1,20090901,,,,145962386,1,HIV infection
14651092,146510926,6,F,,20190219,20180316,20190228,EXP,FR-EMA-20170316-SROYP-090824780,FR-GILEAD-2016-0216060,GILEAD,"RUELLAN AL, VEYRAC G, BRUNET-CARTIER C, JARNET L, JOLLIET P. ETONOGESTREL AND EFAVIRENZ DRUG INTERACTION: RISK OF CONTRACEPTION INEFFICACY. FUNDAMENTAL AND CLINICAL PHARMACOLOGY. 2016;30 (1):50",32,YR,A,F,Y,,,20190228,,OT,FR,FR,EFAVIRENZ.,Maternal exposure during pregnancy,,,,,146510926,1,2009,,,,146510926,1,HIV infection
14674924,146749244,4,F,20180304,20190319,20180323,20190322,EXP,,CO-AUROBINDO-AUR-APL-2018-016866,AUROBINDO,,26,YR,,M,Y,105,KG,20190322,,PH,CO,CO,Efavirenz 600mg,Arthralgia;Diarrhoea;Headache;Pyrexia;Treatment noncompliance;Vomiting,146749244,HO,,,146749244,1,20180226,,,,146749244,1,HIV infection
14790646,147906464,4,F,,20190205,20180423,20190211,EXP,,PT-MYLANLABS-2018M1025394,MYLAN,,27,YR,,F,Y,,,20190211,,OT,PT,PT,EFAVIRENZ.,Caesarean section;Drug abuse;Live birth;Maternal exposure during pregnancy;Pregnancy on oral contraceptive;Product use issue,147906464,OT,,,147906464,1,2007,,,,147906464,1,HIV infection
14850446,148504462,2,F,,20190312,20180505,20190320,EXP,,FR-AUROBINDO-AUR-APL-2018-024204,AUROBINDO,,,,,,Y,,,20190320,,OT,FR,FR,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Myositis,148504462,OT,,,,,,,,,148504462,1,HIV infection
14940798,149407984,4,F,20170908,20181010,20180525,20190108,EXP,,ZA-MYLANLABS-2018M1033998,MYLAN,,0,YR,,F,Y,1.67,KG,20190108,,CN,ZA,ZA,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Neonatal respiratory distress,149407984,CA,,,149407984,1,20170908,20171105,,,149407984,1,Product used for unknown indication
15000172,150001723,3,F,2017,20190319,20180612,20190322,EXP,,CO-AUROBINDO-AUR-APL-2018-031555,AUROBINDO,,39,YR,,M,Y,68.3,KG,20190322,,PH,CO,CO,EFAVIRENZ.,Treatment failure;Viral load increased,150001723,OT,,,150001723,1,201607,,,,150001723,1,HIV infection
15009609,150096093,3,F,,20190227,20180614,20190312,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-050860,BRISTOL MYERS SQUIBB,,55,YR,,M,Y,,,20190312,,OT,GB,GB,EFAVIRENZ.,Toxicity to various agents,150096093,OT,,,,,,,,,150096093,1,HIV infection
15115814,151158145,5,F,20171006,20190304,20180706,20190307,EXP,,GB-MYLANLABS-2018M1048354,MYLAN,,16,WK,,M,Y,,,20190307,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,151158145,OT,,,151158145,1,20171006,20180205,,,151158145,1,HIV infection
15123625,1512362510,10,F,20180205,20190123,20180710,20190131,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190131,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy;Product use issue,1512362510,OT,,,1512362510,1,20171006,20180205,,,1512362510,1,HIV infection
15123626,1512362610,10,F,20180112,20190123,20180710,20190131,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190131,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362610,CA,,,1512362610,1,20171006,20180205,,,1512362610,1,Product used for unknown indication
15127694,151276942,2,F,,20190322,20180710,20190329,EXP,,DE-MYLANLABS-2018M1031482,MYLAN,,25,YR,,F,Y,,,20190329,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151276942,OT,,,,,,,,,151276942,1,Product used for unknown indication
15144564,151445642,2,F,,20190312,20180713,20190319,EXP,,DE-MYLANLABS-2018M1031509,MYLAN,,43,YR,,F,Y,,,20190319,,OT,DE,DE,EFAVIRENZ.,Drug resistance;Gene mutation;Viral mutation identified,151445642,OT,,,,,,,,,151445642,1,Product used for unknown indication
15152012,151520125,5,F,,20190102,20180717,20190114,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063262,BRISTOL MYERS SQUIBB,,,,N,F,Y,,,20190114,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,151520125,CA,,,151520125,1,20110301,20180601,,,151520125,1,Product used for unknown indication
15192933,151929332,2,F,20150608,20190210,20180725,20190220,EXP,FR-EMA-DD-20171219-SHAEVHP-101717,FR-ACCORD-069879,ACCORD,,0,DY,,M,Y,2.64,KG,20190220,,MD,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Foetal growth restriction;Low birth weight baby;Muscle atrophy;Small for dates baby,151929332,OT,,,151929332,4,20150608,20150608,,,151929332,1,Product used for unknown indication
15238115,152381155,5,F,2014,20190301,20180803,20190315,EXP,,ES-AUROBINDO-AUR-APL-2018-039058,AUROBINDO,,,,,,Y,,,20190315,,OT,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,152381155,OT,,,152381155,1,2012,,,,152381155,1,HIV infection
15317962,153179622,2,F,20171006,20190124,20180824,20190130,EXP,,PHHY2018GB074559,SANDOZ,,,,,M,Y,,,20190130,,OT,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153179622,OT,,,,,,,,,153179622,1,Foetal exposure during pregnancy
15372370,153723703,3,F,20090930,20190125,20180911,20190205,EXP,FR-EMA-20130214-MMEVHUMANWT-150034270,FR-GILEAD-2018-0362320,GILEAD,,19,YR,A,F,Y,,,20190205,,CN,FR,FR,SUSTIVA,Caesarean section;Drug ineffective;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive;Unintended pregnancy,153723703,OT,,,153723703,6,20080918,,,,153723703,1,HIV infection
15398444,153984447,7,F,2002,20190215,20180918,20190225,EXP,,PT-MYLANLABS-2018M1068194,MYLAN,"MARTINS S, QUINAZ C, XARA S, VASCONCELOS O, VICENTE P, SARMENTO-CASTRO R.. AIDS ? RELATED PRIMARY PULMONARY LYMPHOMA.. REVISTA PORTUGUESA DE DOENCAS INFECCIOSAS.. 2017;13 (3):142-5",55,YR,,M,Y,,,20190225,,OT,PT,PT,EFAVIRENZ.,Condition aggravated;Multiple organ dysfunction syndrome;Pneumocystis jirovecii pneumonia;Pneumonia pneumococcal;Pulmonary tuberculosis;Respiratory failure;Respiratory symptom;Septic shock;Treatment failure,153984447,OT,,,153984447,4,1997,,,,153984447,1,HIV infection
15438733,154387333,3,F,,20190129,20180928,20190205,EXP,,UG-AUROBINDO-AUR-APL-2018-048507,AUROBINDO,,36,WK,,,Y,2.2,KG,20190205,,MD,UG,UG,EFAVIRENZ.,Ankyloglossia congenital;Foetal exposure during pregnancy;Premature baby,154387333,OT,,,154387333,1,20171030,20180302,,,154387333,1,HIV infection
15456648,154566483,3,F,,20190307,20181002,20190313,EXP,,GB-MYLANLABS-2018M1071213,MYLAN,,,,,F,Y,,,20190313,,OT,ZA,GB,EFAVIRENZ.,Hypertension;Liver function test increased;Maternal exposure during breast feeding;Maternal exposure during pregnancy;Product use issue;Stillbirth,154566483,OT,,,,,,,,,154566483,1,HIV infection
15473109,154731097,7,F,,20190110,20181008,20190222,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-092264,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20190222,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,154731097,LT,,,,,,,,,154731097,1,Chronic hepatitis C
15476035,154760353,3,F,,20190205,20181009,20190215,EXP,,FR-AUROBINDO-AUR-APL-2018-010078,AUROBINDO,,,,,,Y,,,20190215,,OT,FR,FR,EFAVIRENZ.,Haematotoxicity,154760353,OT,,,154760353,1,200709,200804,,,154760353,1,Chronic hepatitis C
15515252,155152523,3,F,,20190302,20181017,20190315,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-078173,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190315,,OT,PT,PT,EFAVIRENZ.,Neuropsychiatric symptoms,155152523,OT,,,,,,,,,155152523,1,Chronic hepatitis C
15515872,155158724,4,F,200101,20190130,20181017,20190213,EXP,,FR-AUROBINDO-AUR-APL-2018-050974,AUROBINDO,,,,,,Y,,,20190213,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified,155158724,OT,,,,,,,,,155158724,1,HIV infection
15548548,155485485,5,F,,20190107,20181025,20190120,EXP,,PT-AUROBINDO-AUR-APL-2018-051917,AUROBINDO,,29,YR,,M,Y,,,20190120,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,155485485,LT,,,,,,,,,155485485,1,Hepatitis C
15573679,155736792,2,F,,20190125,20181101,20190129,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,,M,Y,,,20190129,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,155736792,OT,,,,,,,,,155736792,1,HIV infection
15586886,155868862,2,F,200507,20190206,20181105,20190213,EXP,,FR-GILEAD-2018-0371637,GILEAD,,42,YR,A,F,Y,,,20190213,,MD,FR,FR,EFAVIRENZ.,Blood HIV RNA increased;Drug ineffective;Therapy cessation,155868862,OT,,,155868862,1,200308,200507,,,155868862,1,HIV infection
15609108,156091083,3,F,2018,20190129,20181112,20190205,EXP,,UG-MYLANLABS-2018M1084907,MYLAN,,,,,F,Y,3.8,KG,20190205,,OT,UG,UG,TENOFOVIR DF/LAMIVUDINE/EFAVIRENZ TABLETS 300/300/600MG,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy;Sepsis neonatal;Umbilical granuloma,156091083,OT,,,156091083,1,20180518,,,,156091083,1,HIV infection
15613650,156136503,3,F,2018,20190206,20181113,20190213,EXP,,UG-MYLANLABS-2018M1085392,MYLAN,,,,,M,Y,3.48,KG,20190213,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156136503,OT,,,156136503,1,20180220,,,,156136503,1,HIV infection
15615161,156151612,2,F,,20181215,20181114,20190122,EXP,,UG-HETERO CORPORATE-HET2018UG01328,HETERO,,,,,M,Y,3.5,KG,20190122,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156151612,OT,,,156151612,1,20180220,20180412,,,156151612,1,HIV infection
15617418,156174182,2,F,2018,20190131,20181114,20190208,EXP,,UG-MYLANLABS-2018M1086623,MYLAN,,,,I,M,Y,,,20190208,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174182,OT,,,156174182,1,20180523,,,,156174182,1,Product used for unknown indication
15617422,156174223,3,F,,20190131,20181114,20190208,EXP,,UG-MYLANLABS-2018M1086638,MYLAN,,,,,F,Y,2.93,KG,20190208,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174223,CA,,,156174223,1,20180510,,,,156174223,1,HIV infection
15617481,156174813,3,F,,20190205,20181114,20190219,EXP,,UG-MYLANLABS-2018M1086627,MYLAN,,,,N,F,Y,,,20190219,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156174813,OT,,,156174813,1,20180510,,,,156174813,1,HIV infection
15618298,156182983,3,F,2018,20190201,20181114,20190211,EXP,,UG-MYLANLABS-2018M1086636,MYLAN,,0,YR,,F,Y,,,20190211,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Foetal exposure during pregnancy;Premature baby;Talipes,156182983,CA,,,156182983,1,20180521,,,,156182983,1,HIV infection
15619814,156198144,4,F,,20190131,20181115,20190213,EXP,,UG-AUROBINDO-AUR-APL-2018-054474,AUROBINDO,,,,,,Y,,,20190214,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156198144,CA,,,156198144,1,20180322,,,,156198144,1,HIV infection
15619938,156199385,5,F,,20190206,20181115,20190218,EXP,,UG-AUROBINDO-AUR-APL-2018-054472,AUROBINDO,,,,,,Y,,,20190219,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156199385,CA,,,156199385,1,20180220,,,,156199385,1,HIV infection
15620483,156204834,4,F,,20190114,20181115,20190122,EXP,,UG-AUROBINDO-AUR-APL-2018-054477,AUROBINDO,,,,N,M,Y,2.9,KG,20190122,,MD,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156204834,CA,,,156204834,1,20180213,,,,156204834,1,HIV infection
15620493,156204934,4,F,,20181221,20181115,20190202,EXP,,UG-AUROBINDO-AUR-APL-2018-054478,AUROBINDO,,,,N,F,Y,3.6,KG,20190202,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156204934,OT,,,156204934,1,20180312,,,,156204934,1,HIV infection
15620496,156204963,3,F,,20190131,20181115,20190214,EXP,,UG-AUROBINDO-AUR-APL-2018-054491,AUROBINDO,,,,,,Y,,,20190214,,MD,UG,UG,EFAVIRENZ.,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156204963,OT,,,156204963,1,20180301,,,,156204963,1,HIV infection
15621343,156213432,2,F,2018,20190131,20181115,20190208,EXP,,UG-MYLANLABS-2018M1086698,MYLAN,,0,YR,,M,Y,,,20190208,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156213432,OT,,,156213432,1,20180412,,,,156213432,1,HIV infection
15621559,156215593,3,F,2018,20190205,20181115,20190218,EXP,,UG-MYLANLABS-2018M1086624,MYLAN,,,,N,F,Y,3.5,KG,20190218,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156215593,CA,,,156215593,1,20180404,,,,156215593,1,HIV infection
15622136,156221362,2,F,2018,20190207,20181115,20190214,EXP,,UG-MYLANLABS-2018M1086990,MYLAN,,0,YR,,F,Y,3,KG,20190214,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy,156221362,OT,,,156221362,1,20180412,,,,156221362,1,Product used for unknown indication
15622930,156229303,3,F,2018,20190205,20181115,20190218,EXP,,UG-MYLANLABS-2018M1086629,MYLAN,,,,,M,Y,3.13,KG,20190218,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156229303,OT,,,156229303,1,20180328,,,,156229303,1,HIV infection
15624537,156245374,4,F,,20190119,20181116,20190202,EXP,,PT-AUROBINDO-AUR-APL-2018-055802,AUROBINDO,,49,YR,,M,Y,,,20190202,,OT,PT,PT,Efavirenz Film Coated Tablets,Acute kidney injury;Hepatotoxicity;Tubulointerstitial nephritis,156245374,OT,,,,,,,,,156245374,1,HIV infection
15624816,156248163,3,F,,20190201,20181116,20190215,EXP,,UG-CIPLA (EU) LIMITED-2018UG22544,CIPLA,,,,,,Y,,,20190215,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156248163,CA,,,,,,,,,,,
15624938,156249384,4,F,,20190201,20181116,20190215,EXP,,UG-CIPLA (EU) LIMITED-2018UG22539,CIPLA,,,,,,Y,,,20190215,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156249384,OT,,,,,,,,,,,
15626058,156260582,2,F,2018,20190131,20181116,20190208,EXP,,UG-MYLANLABS-2018M1086715,MYLAN,,,,N,F,Y,,,20190208,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156260582,CA,,,156260582,1,20180322,,,,156260582,1,HIV infection
15627005,156270054,4,F,2018,20190129,20181116,20190205,EXP,,UG-MYLANLABS-2018M1087001,MYLAN,,,,N,M,Y,3.21,KG,20190205,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Congenital umbilical hernia;Foetal exposure during pregnancy;Polydactyly,156270054,CA,,,156270054,1,20180605,,,,156270054,1,HIV infection
15627007,156270072,2,F,2018,20190131,20181116,20190208,EXP,,UG-MYLANLABS-2018M1086998,MYLAN,,0,YR,,F,Y,3.12,KG,20190208,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156270072,CA,,,156270072,1,20180301,,,,156270072,1,HIV infection
15627873,156278732,2,F,2018,20190114,20181116,20190121,EXP,,UG-MYLANLABS-2018M1086713,MYLAN,,,,,M,Y,2.99,KG,20190121,,OT,UG,UG,EFAVIRENZ.,Congenital umbilical hernia;Foetal exposure during pregnancy,156278732,OT,,,156278732,1,20180213,,,,156278732,1,HIV infection
15629934,156299342,2,F,,20190201,20181117,20190211,EXP,,UG-MYLANLABS-2018M1086681,MYLAN,,,,I,M,Y,2.8,KG,20190211,,OT,UG,UG,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156299342,OT,,,156299342,1,20180503,,,,156299342,1,HIV infection
15635454,156354542,2,F,20180322,20190109,20181120,20190123,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2018018678,MACLEODS,,,,,,Y,,,20190123,,OT,US,UG,Efavirenz 600 mg,Birth mark;Foetal exposure during pregnancy;Umbilical hernia,156354542,OT,,,156354542,1,20180322,,,,156354542,1,HIV infection
15647188,156471883,3,F,,20190201,20181122,20190207,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009604,STRIDES,,,,,F,Y,3,KG,20190207,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156471883,OT,,,,,,,,,156471883,1,Product used for unknown indication
15658877,156588773,3,F,2018,20190129,20181126,20190205,EXP,,UG-MYLANLABS-2018M1087630,MYLAN,,,,N,F,Y,3.6,KG,20190205,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156588773,OT,,,156588773,1,20180312,,,,156588773,1,HIV infection
15659270,156592703,3,F,,20190207,20181127,20190213,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009590,STRIDES,,,,,M,Y,3,KG,20190213,,CN,US,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,156592703,CA,,,,,,,,,156592703,1,Product used for unknown indication
15660775,156607752,2,F,20180908,20190301,20181127,20190308,EXP,,ID-JNJFOC-20181129492,JANSSEN,,48,YR,A,M,Y,50,KG,20190308,,MD,ID,ID,EFAVIRENZ.,Blood sodium decreased;Dyspepsia;Haemoglobin decreased;Tuberculosis,156607752,HO,,,156607752,1,20180829,20180908,,,156607752,1,Tuberculosis
15674119,156741192,2,F,20161117,20190111,20181129,20190127,PER,,US-JNJFOC-20181121123,JANSSEN,,59,YR,A,M,Y,67.13,KG,20190127,,CN,US,US,SUSTIVA,Rectal haemorrhage,156741192,HO,,,156741192,1,20160822,20161117,,,156741192,1,Deep vein thrombosis
15674688,156746883,3,F,,20181119,20181130,20190205,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-111091,BRISTOL MYERS SQUIBB,,,,,,Y,,,20190205,,OT,IN,ZA,EFAVIRENZ.,Pancreatitis;Prescribed underdose,156746883,OT,,,,,,,,,156746883,1,HIV infection
15702268,157022682,2,F,,20190114,20181209,20190128,EXP,,PT-AUROBINDO-AUR-APL-2018-058727,AUROBINDO,,29,YR,,M,Y,,,20190129,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis;Transaminases increased,157022682,OT,,,,,,,,,157022682,1,Hepatitis C
15708417,157084173,3,F,,20190110,20181211,20190222,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-112504,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20190222,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,157084173,OT,,,,,,,,,157084173,1,HIV infection CDC category C
15730076,157300763,3,F,20180309,20190114,20181217,20190122,EXP,,ZA-GILEAD-2018-0380355,GILEAD,,0,YR,N,M,Y,3.84,KG,20190122,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus,157300763,CA,,,157300763,1,20180309,20180504,,,157300763,1,HIV infection
15732738,157327383,3,F,2018,20190121,20181217,20190131,EXP,,ZA-MYLANLABS-2018M1093660,MYLAN,,0,YR,,M,Y,3.3,KG,20190131,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hernia congenital,157327383,OT,,,157327383,1,20180307,,,,157327383,1,Product used for unknown indication
15736184,157361843,3,F,20180531,20190114,20181218,20190122,EXP,,ZA-GILEAD-2018-0380804,GILEAD,,0,YR,N,F,Y,3.42,KG,20190122,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157361843,OT,,,157361843,1,20180531,20180914,,,157361843,1,HIV infection
15736978,157369782,2,F,,20190201,20181218,20190211,EXP,,ZA-MYLANLABS-2018M1094191,MYLAN,,,,,M,Y,3.66,KG,20190211,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,157369782,OT,,,157369782,1,20180320,,,,157369782,1,Product used for unknown indication
15737050,157370503,3,F,20180405,20190115,20181218,20190122,EXP,,ZA-GILEAD-2018-0380717,GILEAD,,,,N,M,Y,1.85,KG,20190122,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157370503,CA,,,157370503,1,20180405,20180408,,,157370503,1,HIV infection
15740581,157405814,4,F,20180405,20190118,20181219,20190122,EXP,,ZA-GILEAD-2018-0380549,GILEAD,,26,YR,A,F,Y,,,20190122,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Premature delivery,157405814,OT,,,157405814,1,20180405,,,,157405814,1,HIV infection
15740770,157407704,4,F,20180412,20190131,20181219,20190228,EXP,,ZA-GILEAD-2018-0380807,GILEAD,,0,YR,N,M,Y,4,KG,20190228,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157407704,CA,,,157407704,1,20180412,,,,157407704,1,HIV infection
15745897,157458973,3,F,20180320,20181224,20181220,20190122,EXP,,ZA-GILEAD-2018-0380946,GILEAD,,0,YR,N,M,Y,3.66,KG,20190122,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,157458973,CA,,,157458973,1,20180320,20180702,,,157458973,1,HIV infection
15746215,157462152,2,F,,20190206,20181220,20190213,EXP,,ZA-MYLANLABS-2018M1094943,MYLAN,,,,N,F,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157462152,OT,,,157462152,1,20180531,,,,157462152,1,HIV infection
15751695,157516953,3,F,,20181224,20181221,20190311,EXP,,ZA-GILEAD-2018-0381253,GILEAD,,,,N,F,Y,3.28,KG,20190311,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157516953,CA,,,157516953,1,20180524,,,,157516953,1,HIV infection
15757567,157575672,2,F,20090618,20190103,20181224,20190110,EXP,,FR-GILEAD-2018-0381472,GILEAD,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T).. CHEMICAL BIOLOGY + DRUG DESIGN.. 2018;N/A:N/A. DOI:DOI: 10.1111/CBDD.13378",47,YR,A,M,Y,,,20190110,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,157575672,OT,,,,,,,,,157575672,1,HIV infection
15758812,157588122,2,F,,20190214,20181225,20190226,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-117137,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190226,,OT,GB,GB,EFAVIRENZ.,No adverse event,,,,,,,,,,,157588122,1,HIV infection
15760400,157604003,3,F,2018,20190201,20181226,20190211,EXP,,ZA-MYLANLABS-2018M1095054,MYLAN,,0,YR,,M,Y,4,KG,20190211,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157604003,CA,,,157604003,1,20180412,,,,157604003,1,Product used for unknown indication
15763590,157635902,2,F,,20190115,20181227,20190117,EXP,,ZA-GILEAD-2018-0381712,GILEAD,,,,N,F,Y,2.86,KG,20190117,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157635902,CA,,,157635902,1,20180614,,,,157635902,1,HIV infection
15763598,157635983,3,F,20180629,20190114,20181227,20190118,EXP,,ZA-GILEAD-2018-0381700,GILEAD,,0,YR,N,M,Y,3.44,KG,20190118,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,157635983,OT,,,157635983,1,20180629,20180811,,,157635983,1,HIV infection
15766913,157669133,3,F,,20190114,20181227,20190117,EXP,,IT-MYLANLABS-2018M1095303,MYLAN,,,,A,,Y,,,20190117,,MD,IT,IT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiotoxicity;Toxicity to various agents,157669133,OT,,,,,,,,,157669133,1,HIV infection
15767049,157670493,3,F,,20190114,20181227,20190125,EXP,,IT-MYLANLABS-2018M1095299,MYLAN,,,,A,,Y,,,20190125,,MD,IT,IT,EFAVIRENZ.;EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Cardiotoxicity;Drug intolerance;Lipodystrophy acquired,157670493,OT,,,,,,,,,157670493,1,HIV infection
15773439,157734392,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382250,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734392,OT,,,,,,,,,157734392,1,HIV infection
15773441,157734412,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382549,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734412,OT,,,,,,,,,157734412,1,HIV infection
15773442,157734422,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382539,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734422,OT,,,,,,,,,157734422,1,HIV infection
15773443,157734432,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382538,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734432,OT,,,,,,,,,157734432,1,HIV infection
15773444,157734442,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382512,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734442,OT,,,,,,,,,157734442,1,HIV infection
15773446,157734462,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382511,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734462,OT,,,,,,,,,157734462,1,HIV infection
15773452,157734522,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382510,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734522,OT,,,,,,,,,157734522,1,HIV infection
15773453,157734533,3,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382509,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734533,OT,,,,,,,,,157734533,1,HIV infection
15773463,157734632,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382550,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734632,OT,,,,,,,,,157734632,1,HIV infection
15773464,157734643,3,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382523,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734643,OT,,,,,,,,,157734643,1,HIV infection
15773465,157734652,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382527,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734652,OT,,,,,,,,,157734652,1,HIV infection
15773466,157734662,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382541,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734662,OT,,,,,,,,,157734662,1,HIV infection
15773467,157734672,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382524,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734672,OT,,,,,,,,,157734672,1,HIV infection
15773468,157734682,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382537,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734682,OT,,,,,,,,,157734682,1,HIV infection
15773469,157734692,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382525,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734692,OT,,,,,,,,,157734692,1,HIV infection
15773470,157734702,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382551,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734702,OT,,,,,,,,,157734702,1,HIV infection
15773471,157734712,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382526,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734712,OT,,,,,,,,,157734712,1,HIV infection
15773482,157734822,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382508,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:DOI: 10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734822,OT,,,,,,,,,157734822,1,HIV infection
15773483,157734832,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382540,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734832,OT,,,,,,,,,157734832,1,HIV infection
15773484,157734842,2,F,,20190205,20181228,20190213,EXP,,ZA-GILEAD-2018-0382548,GILEAD,FOUCHE C. VAN NIEKERK E. DU PLESSIS L.M.. ANTHROPOMETRIC PARAMETERS OF HIV-INFECTED AND HIV-UNINFECTED MOTHERS AND THEIR PREMATURE INFANTS.. JOURNAL OF TROPICAL PEDIATRICS.. 2018;64(4):255-261. DOI:10.1093/TROPEJ/FMX056,,,N,,Y,,,20190213,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Foetal growth restriction,157734842,OT,,,,,,,,,157734842,1,HIV infection
15779141,157791414,4,F,,20190201,20190101,20190211,EXP,,ZA-MYLANLABS-2018M1095419,MYLAN,,,,N,F,Y,3.28,KG,20190211,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital acrochordon;Foetal exposure during pregnancy,157791414,CA,,,157791414,1,20180524,,,,157791414,1,HIV infection
15780547,157805471,1,I,,20181217,20190102,20190102,EXP,,ZA-MYLANLABS-2018M1095422,MYLAN,,,,,M,Y,,,20190101,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,157805471,CA,,,157805471,1,20180208,,,,157805471,1,HIV infection
15784943,157849431,1,I,20131007,20131023,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08317,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Death;Malnutrition,157849431,DE,,,157849431,1,20130924,20131007,,,157849431,1,HIV infection
15784956,157849561,1,I,20130822,20130823,20190103,20190103,EXP,,KE-CIPLA (EU) LIMITED-2016KE08314,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Acute respiratory distress syndrome;Alanine aminotransferase increased;Hyperkalaemia;Immune reconstitution inflammatory syndrome;Intestinal obstruction;Pulmonary embolism;Pulmonary tuberculosis;Pyrexia;Sepsis,157849561,DE,,,157849561,1,20130815,20130824,,,157849561,1,HIV infection
15784965,157849651,1,I,,20140227,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08319,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Death,157849651,DE,,,157849651,1,20140128,20140224,,,157849651,1,HIV infection
15785010,157850101,1,I,20140129,20140204,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08333,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Meningitis bacterial;Meningitis tuberculous;Myelitis transverse;Neuropathy peripheral;Oral candidiasis;Urinary retention,157850101,OT,,,157850101,1,20140114,20140227,,,157850101,1,HIV infection
15785022,157850221,1,I,,20140129,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08318,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Death,157850221,DE,,,157850221,1,20131205,20140127,,,157850221,1,HIV infection
15785036,157850361,1,I,20130827,20130830,20190103,20190103,EXP,,KE-CIPLA LTD.-2016KE08316,CIPLA,,,,,,Y,,,20190103,,OT,KE,KE,EFAVIRENZ.,Acute kidney injury;Anaemia;Death;Lymphopenia;Pulmonary tuberculosis,157850361,HO,,,157850361,1,20130822,20130830,,,157850361,1,HIV infection
15786142,157861421,1,I,20181020,20181224,20190103,20190103,EXP,,PG-JNJFOC-20181231772,JANSSEN,,27,YR,A,F,Y,45,KG,20190103,,MD,PG,PG,EFAVIRENZ.,Hepatotoxicity,157861421,OT,,,157861421,1,20180905,20181214,,,157861421,1,Tuberculosis
15795852,157958521,1,I,,20190103,20190107,20190107,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-122302,BRISTOL MYERS SQUIBB,,,,A,,Y,,,20190107,,MD,GB,GB,EFAVIRENZ.,Hepatitis B,157958521,OT,,,,,,,,,157958521,1,HIV infection
15796694,157966942,2,F,,20181228,20190108,20190108,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-122768,BRISTOL MYERS SQUIBB,,39,YR,,M,Y,,,20190108,,OT,US,US,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Immune reconstitution inflammatory syndrome;Psoriasis,157966942,OT,,,,,,,,,157966942,1,HIV infection
15798153,157981533,3,F,2018,20190131,20190108,20190214,EXP,,ZA-MYLANLABS-2019M1001012,MYLAN,,,,N,M,Y,3.44,KG,20190214,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,157981533,CA,,,157981533,1,20180629,,,,157981533,1,Product used for unknown indication
15798355,157983551,1,I,,20181226,20190108,20190108,EXP,,"IN-LANNETT COMPANY, INC.-IN-2018LAN004652",LANNETT,"BALASWAMY REDDY G, SRINIVAS G. ATYPICAL PSYCHOPATHOLOGY AND CLINICAL CHALLENGES IN TREATING A PATIENT WITH HIV-ASSOCIATED NEUROCOGNITIVE DISORDER. HIV-AIDS-REV. 2018;17(3):224-226",,,A,M,Y,,,20190108,,MD,IN,IN,EFAVIRENZ.,HIV-associated neurocognitive disorder;Psychotic disorder,157983551,OT,,,,,,,,,157983551,1,HIV infection
15799851,157998511,1,I,,20181231,20190108,20190108,EXP,,CN-MYLANLABS-2019M1000917,MYLAN,"XIAO J, DU S, DAI G, GAO G, YANG D, ZHAO H. EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN CHINESE PATIENTS WITH AIDS-RELATED BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: AN OBSERVATIONAL STUDY. SCI-REP 2017;7:NO. 1.",,,A,M,Y,,,20190108,,OT,CN,CN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Renal failure,157998511,DE,,,,,,,,,157998511,1,Burkitt's lymphoma
15800297,158002971,1,I,,20190103,20190108,20190108,EXP,,CA-GILEAD-2019-0383284,GILEAD,,45,YR,A,M,Y,,,20190108,,OT,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,158002971,OT,,,,,,,,,158002971,1,HIV infection
15801503,158015032,2,F,2018,20190117,20190109,20190125,EXP,,ZA-MYLANLABS-2019M1001015,MYLAN,,,,N,F,Y,2.86,KG,20190125,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158015032,CA,,,158015032,1,20180614,,,,158015032,1,Product used for unknown indication
15801533,158015331,1,I,,20181231,20190109,20190109,EXP,,CN-MYLANLABS-2019M1000923,MYLAN,"XIAO J, DU S, DAI G, GAO G, YANG D, ZHAO H. EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN CHINESE PATIENTS WITH AIDS-RELATED BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: AN OBSERVATIONAL STUDY. SCI-REP 2017;7:NO. 1.",,,A,M,Y,,,20190109,,OT,CN,CN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Haemorrhage,158015331,DE,,,,,,,,,158015331,1,Burkitt's lymphoma
15806118,158061182,2,F,,20190201,20190110,20190205,EXP,,UG-STRIDES ARCOLAB LIMITED-2018SP009587,STRIDES,,,,,F,Y,3.5,KG,20190205,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158061182,OT,,,158061182,1,20180322,,,,158061182,1,Product used for unknown indication
15807772,158077721,1,I,20190104,20190107,20190110,20190110,PER,,US-CELGENEUS-USA-20190102124,CELGENE,,57,YR,,M,Y,99.88,KG,20190110,,OT,US,US,EFAVIRENZ.,Chest pain,158077721,HO,,,158077721,1,20180906,,,,158077721,1,Kaposi's sarcoma
15813826,158138262,2,F,,20190108,20190111,20190121,EXP,,CA-MYLANLABS-2019M1002112,MYLAN,,44,YR,,M,Y,61,KG,20190121,,PH,CA,CA,Mylan-Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Drug ineffective,158138262,OT,,,,,,,,,158138262,1,HIV infection
15820413,158204131,1,I,,20181231,20190114,20190114,EXP,,CN-MYLANLABS-2019M1000915,MYLAN,"XIAO J, DU S, DAI G, GAO G, YANG D, ZHAO H. EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN CHINESE PATIENTS WITH AIDS-RELATED BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: AN OBSERVATIONAL STUDY. SCI-REP 2017;7:NO. 1.",,,A,M,Y,,,20190114,,OT,CN,CN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Arrhythmia,158204131,DE,,,,,,,,,158204131,1,Burkitt's lymphoma
15820419,158204191,1,I,,20181231,20190114,20190114,EXP,,CN-MYLANLABS-2019M1000912,MYLAN,"XIAO J, DU S, DAI G, GAO G, YANG D, ZHAO H. EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN CHINESE PATIENTS WITH AIDS-RELATED BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: AN OBSERVATIONAL STUDY. SCI-REP 2017;7:NO. 1.",,,A,,Y,,,20190114,,OT,CN,CN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Renal failure,158204191,DE,,,,,,,,,158204191,1,Diffuse large B-cell lymphoma
15820420,158204201,1,I,,20181231,20190114,20190114,EXP,,CN-MYLANLABS-2019M1000909,MYLAN,"XIAO J, DU S, DAI G, GAO G, YANG D, ZHAO H. EFFICACY AND TOLERABILITY OF CHEMOTHERAPY IN CHINESE PATIENTS WITH AIDS-RELATED BURKITT LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA: AN OBSERVATIONAL STUDY. SCI-REP 2017;7:NO. 1.",,,A,,Y,,,20190114,,OT,CN,CN,EFAVIRENZ + LAMIVUDINE + TENOFOVIR,Bone marrow failure,158204201,OT,,,,,,,,,158204201,1,Diffuse large B-cell lymphoma
15821563,158215631,1,I,2018,20190108,20190114,20190114,EXP,,UG-MYLANLABS-2019M1002701,MYLAN,,,,,F,Y,3.5,KG,20190114,,OT,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158215631,OT,,,158215631,1,20180322,,,,158215631,1,Product used for unknown indication
15824722,158247221,1,I,,20190108,20190115,20190115,EXP,,CA-ABBVIE-19S-028-2618488-00,ABBVIE,,54,YR,,M,Y,,,20190115,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,158247221,OT,,,,,,,,,158247221,1,HIV infection
15826893,158268931,1,I,20181218,20190111,20190115,20190115,PER,,US-BAYER-2019-010385,BAYER,,34,YR,A,M,Y,44.22,KG,20190115,,OT,US,US,EFAVIRENZ.,Hypoaesthesia;Neuropathy peripheral;Paraesthesia,158268931,DS,,,158268931,1,20180316,201812,,,158268931,1,Tuberculosis
15828303,158283032,2,F,20180322,20190131,20190115,20190207,EXP,,UG-GILEAD-2018-0373403,GILEAD,,0,YR,N,F,Y,3.5,KG,20190207,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158283032,OT,,,158283032,1,20180322,,,,158283032,1,HIV infection
15830514,158305141,1,I,,20190109,20190115,20190115,EXP,GB-MHRA-EYC 00181639,GB-MYLANLABS-2019M1003224,MYLAN,,,,N,F,Y,,,20190115,,MD,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Polydactyly,158305141,CA,,,158305141,1,201103,201806,,,158305141,1,HIV infection
15832748,158327481,1,I,,20190108,20190116,20190116,EXP,,ZA-MYLANLABS-2019M1003076,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190116,,MD,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction;Protein-losing gastroenteropathy;Sepsis;Tuberculosis gastrointestinal,158327481,DE,,,,,,,,,158327481,1,HIV infection
15832758,158327582,2,F,20180322,20190131,20190116,20190208,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018236801,VIIV,,0,YR,,F,Y,3.5,KG,20190208,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158327582,CA,,,158327582,1,20180322,,,,158327582,1,HIV infection
15834946,158349462,2,F,,20190225,20190116,20190304,EXP,,FR-GILEAD-2019-0384132,GILEAD,,37,YR,A,M,Y,,,20190304,,OT,IT,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,158349462,OT,,,,,,,,,158349462,1,HIV infection
15835920,158359203,3,F,,20190114,20190117,20190128,EXP,,ZA-AUROBINDO-AUR-APL-2019-001256,AUROBINDO,,,,I,M,Y,3.4,KG,20190129,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy,158359203,CA,,,158359203,1,20180629,,,,158359203,1,HIV infection
15836280,158362803,3,F,,20190129,20190117,20190208,EXP,,ZA-AUROBINDO-AUR-APL-2019-001293,AUROBINDO,,,,,,Y,,,20190208,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Foetal exposure during pregnancy;Strabismus congenital,158362803,OT,,,158362803,1,20180208,,,,158362803,1,HIV infection
15836338,158363383,3,F,,20190128,20190117,20190208,EXP,,ZA-AUROBINDO-AUR-APL-2019-001255,AUROBINDO,,,,,,Y,,,20190208,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital acrochordon;Foetal exposure during pregnancy,158363383,CA,,,158363383,1,20180524,,,,158363383,1,HIV infection
15836406,158364063,3,F,,20190206,20190117,20190218,EXP,,ZA-AUROBINDO-AUR-APL-2019-001288,AUROBINDO,,,,,,Y,,,20190219,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy,158364063,CA,,,158364063,1,20180531,,,,158364063,1,HIV infection
15836618,158366182,2,F,,20190115,20190117,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001251,AUROBINDO,,,,,M,Y,1.8,KG,20190129,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158366182,OT,,,158366182,1,20180405,,,,158366182,1,HIV infection
15837621,158376211,1,I,,20190108,20190117,20190117,EXP,,ZA-MYLANLABS-2019M1003075,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190117,,MD,ZA,ZA,EFAVIRENZ.,Cardiac tamponade;Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction,158376211,DE,,,,,,,,,158376211,1,HIV infection
15838467,158384675,5,F,20171006,20190304,20190117,20190307,EXP,,GB-MYLANLABS-2019M1001573,MYLAN,,43,YR,,F,Y,,,20190307,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,158384675,OT,,,,,,,,,158384675,1,HIV infection
15839001,158390011,1,I,,20181212,20190117,20190117,EXP,,ZA-GILEAD-2018-0380353,GILEAD,,,,I,M,Y,33.3,KG,20190117,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Hernia congenital,158390011,CA,,,158390011,1,20180307,,,,158390011,1,HIV infection
15839144,158391442,2,F,20110825,20190109,20190117,20190117,EXP,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-123520,IT-JNJFOC-20190115342,JANSSEN,"POUGA  L, SANTORO  MM, CHARPENTIER  C, CARLO  DD, ROMEO  I, ARTESE  A. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY AND DRUG DESIGN 2018:1-10.",37,YR,A,M,Y,,,20190117,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Viral mutation identified,158391442,OT,,,,,,,,,158391442,1,HIV infection
15839390,158393902,2,F,20180322,20190131,20190117,20190208,EXP,,UG-GLAXOSMITHKLINE-UG2018236801,GLAXOSMITHKLINE,,0,YR,,F,Y,3.5,KG,20190208,,MD,UG,UG,EFAVIRENZ.,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,158393902,OT,,,158393902,1,20180322,,,,158393902,1,HIV infection
15839428,158394282,2,F,201610,20190201,20190117,20190207,EXP,,GB-MYLANLABS-2019M1003653,MYLAN,"SUTTON N, GUPTA N.. HIV-POSITIVE WOMEN AND CONTRACEPTION; EFFICACY VERSUS ACCEPTABILITY. HIV MEDICINE. 2018;19 (SUPPL. 2):S21?S152",38,YR,,F,Y,,,20190207,,,COUNTRY NOT SPECIFIED,GB,EFAVIRENZ.,Abortion induced;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,158394282,OT,,,158394282,1,201106,,,,158394282,1,HIV infection
15839587,158395871,1,I,,20190108,20190117,20190117,EXP,,ZA-MYLANLABS-2019M1003211,MYLAN,"MEINTJES G, STEK C, BLUMENTHAL L, THIENEMANN F, SCHUTZ C, BUYZE J, ET AL. PREDNISONE FOR THE PREVENTION OF PARADOXICAL TUBERCULOSIS-ASSOCIATED IRIS. N-ENGL-J-MED 2018;379(20):1915-1925.",,,A,,Y,,,20190117,,MD,ZA,ZA,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis;Paradoxical drug reaction,158395871,DE,,,,,,,,,158395871,1,HIV infection
15845850,158458501,1,I,201808,20190107,20190120,20190120,EXP,,PT-AUROBINDO-AUR-APL-2019-001642,AUROBINDO,,45,YR,,M,Y,,,20190120,,PH,PT,PT,EFAVIRENZ.,Insomnia;Nightmare,158458501,OT,,,158458501,1,20130702,20181217,,,158458501,1,HIV infection
15847615,158476152,2,F,,20190121,20190121,20190203,EXP,,TZ-AUROBINDO-AUR-APL-2019-001287,AUROBINDO,,,,,M,Y,2.3,KG,20190204,,MD,TZ,TZ,"Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate",Foetal exposure during pregnancy;Haemangioma,158476152,CA,,,158476152,1,20180510,20180516,,,158476152,1,HIV infection
15847693,158476932,2,F,,20190115,20190121,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001247,AUROBINDO,,42,WK,,M,Y,3.6,KG,20190129,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Cleft palate;Congenital umbilical hernia;Foetal exposure during pregnancy,158476932,CA,,,158476932,1,20180320,,,,158476932,1,HIV infection
15849719,158497192,2,F,2018,20190124,20190121,20190131,EXP,,ZA-MYLANLABS-2019M1004469,MYLAN,,,,,M,Y,3.4,KG,20190131,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,158497192,CA,,,158497192,1,20180629,,,,158497192,1,Product used for unknown indication
15852189,158521891,1,I,,20190109,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-003208,BRISTOL MYERS SQUIBB,,29,YR,,M,Y,,,20190122,,MD,IN,IN,EFAVIRENZ.,Angioedema;Pruritus;Therapeutic product cross-reactivity,158521891,OT,,,,,,,,,158521891,1,Antiretroviral therapy
15852229,158522291,1,I,,20190109,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-005406,BRISTOL MYERS SQUIBB,,45,YR,,F,Y,,,20190122,,MD,IN,IN,EFAVIRENZ.,Rash macular;Therapeutic product cross-reactivity,158522291,OT,,,,,,,,,158522291,1,Antiretroviral therapy
15852544,158525441,1,I,,20190109,20190122,20190122,EXP,,IN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-005407,BRISTOL MYERS SQUIBB,,36,YR,,F,Y,,,20190122,,MD,IN,IN,EFAVIRENZ.,Rash maculo-papular;Therapeutic product cross-reactivity,158525441,OT,,,,,,,,,158525441,1,Antiretroviral therapy
15854101,158541012,2,F,20181127,20190301,20190122,20190305,EXP,FR-AFSSAPS-NC20190054,FR-ABBVIE-19S-056-2634604-00,ABBVIE,,52,YR,,M,Y,46,KG,20190305,,MD,FR,FR,EFAVIRENZ.,Muscular weakness;Paresis;Renal tubular disorder,158541012,LT,,,158541012,2,20180815,20181015,,,158541012,1,HIV infection
15854148,158541481,1,I,,20190115,20190122,20190122,EXP,,JP-JNJFOC-20190124555,JANSSEN,,57,YR,A,M,Y,,,20190122,,MD,JP,JP,EFAVIRENZ.,Burkitt's lymphoma;Cytomegalovirus chorioretinitis,158541481,OT,,,,,,,,,158541481,1,Kaposi's sarcoma
15854173,158541731,1,I,,,20190121,20190121,DIR,,,FDA-CTU,,74,YR,,M,N,65.25,KG,20190121,N,OT,US,US,SUSTIVA,Disease progression,158541731,OT,158541731,HP,158541731,1,20181002,20190121,,,158541731,1,Prostate cancer
15855785,158557851,1,I,20150608,20190117,20190122,20190122,EXP,,FR-MYLANLABS-2019M1005201,MYLAN,,37,YR,,F,Y,,,20190122,,CN,US,FR,SUSTIVA,Foetal growth restriction;Live birth;Maternal exposure during pregnancy,158557851,OT,,,158557851,6,20150608,20150608,,,158557851,1,Product used for unknown indication
15856736,158567362,2,F,,20190121,20190123,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-002466,AUROBINDO,,,,,,Y,,,20190202,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Foetal exposure during pregnancy;Hernia congenital,158567362,OT,,,158567362,1,20180307,,,,158567362,1,HIV infection
15857832,158578322,2,F,,20190115,20190123,20190124,EXP,,JP-JNJFOC-20190124613,JANSSEN,,40,YR,A,M,Y,,,20190124,,MD,JP,JP,EFAVIRENZ.,Acute respiratory distress syndrome;Dyspnoea;Haemophagocytic lymphohistiocytosis;Lymphoma,158578322,OT,,,,,,,,,158578322,1,Kaposi's sarcoma
15861434,158614341,1,I,,20171120,20190124,20190124,EXP,,CN-ROCHE-2241092,ROCHE,,21,YR,,M,Y,,,20190124,,MD,CN,CN,EFAVIRENZ.,Flatulence;Hypermetabolism;Pelvic cyst;Pelvic fluid collection;Positron emission tomogram abnormal,158614341,OT,,,,,,,,,158614341,1,Lymphoma AIDS related
15863660,158636601,1,I,201805,20190122,20190124,20190124,EXP,,US-GILEAD-2019-0386262,GILEAD,,73,YR,E,M,Y,,,20190124,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Depressed mood;Frustration tolerance decreased;Myocardial infarction;Product prescribing issue;Suicide threat,158636601,OT,,,,,,,,,158636601,1,Product used for unknown indication
15865337,158653371,1,I,20110825,20190110,20190124,20190124,EXP,,FR-AUROBINDO-AUR-APL-2019-002782,AUROBINDO,,37,YR,,M,Y,,,20190125,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,158653371,OT,,,,,,,,,158653371,1,HIV infection
15866879,158668792,2,F,,20190121,20190125,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-002420,AUROBINDO,,,,,,Y,,,20190202,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Foetal exposure during pregnancy;Strabismus,158668792,CA,,,158668792,1,20180309,,,,158668792,1,HIV infection
15867711,158677111,1,I,,20190118,20190125,20190125,EXP,,GB-MYLANLABS-2019M1006237,MYLAN,,,,A,F,Y,,,20190125,,CN,GB,GB,EFAVIRENZ.,Drug ineffective,158677111,OT,,,,,,,,,158677111,1,Product used for unknown indication
15868666,158686662,2,F,20180806,20190205,20190125,20190212,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK143246,VIIV,,12,WK,,,Y,,,20190212,,MD,UG,UG,EFAVIRENZ.,Sudden infant death syndrome,158686662,DE,,,158686662,1,20180328,,,,158686662,1,HIV infection
15874853,158748531,1,I,20041201,20060718,20190126,20190126,EXP,,FR-ABBVIE-06P-056-0338441-00,ABBVIE,,57,YR,,M,Y,49,KG,20190126,,OT,FR,FR,SUSTIVA,Aminoaciduria;Blood creatine increased;Fanconi syndrome;Hypophosphataemia;Proteinuria;Renal failure,158748531,HO,,,158748531,1,20030901,20060408,,,158748531,1,HIV infection
15877428,158774281,1,I,20060710,20060929,20190128,20190128,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2006-FF-00981FF",BOEHRINGER INGELHEIM,,41,YR,,M,Y,55,KG,20190128,,OT,FR,FR,SUSTIVA,Onychomadesis;Pruritus;Rash;Stevens-Johnson syndrome,158774281,HO,,,158774281,1,20060629,20060728,,,158774281,1,Product used for unknown indication
15878506,158785061,1,I,20150906,20190121,20190128,20190128,EXP,,CN-ROCHE-2249754,ROCHE,"MIN H, MIN H, YANG J, WANG S, TAO P, SONG Y, WANG X, LI,  H, YANG X, DONG X, WANG F, SHI M AND XU R REMISSION OF HIV-RELATED NAIVE AND HIGH-RISK BURKITT^S LYMPHOMA TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS CART. STEM CELL RESEARCH AND THERAPY 2018 DEC 20;9(1):-.",27,YR,,M,Y,,,20190128,,OT,CN,CN,EFAVIRENZ.,Bone marrow failure;Lung infection;Neutropenia;Staphylococcal infection;Stomatitis,158785061,OT,,,158785061,1,20150831,20150923,,,158785061,1,Burkitt's lymphoma
15880301,158803011,1,I,20181225,,20190104,20190104,DIR,,,FDA-CTU,,29,YR,,M,N,,,20190103,N,OT,US,US,EFAVIRENZ.,Bipolar I disorder,,,158803011,HP,158803011,1,20181005,,,,158803011,1,HIV infection
15882518,158825182,2,F,,20190115,20190129,20190129,EXP,,ZA-AUROBINDO-AUR-APL-2019-001283,AUROBINDO,,,,,F,Y,2.8,KG,20190129,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital umbilical hernia;Foetal exposure during pregnancy;Premature baby,158825182,OT,,,158825182,1,20180614,,,,158825182,1,HIV infection
15884519,158845191,1,I,,20190122,20190129,20190129,EXP,,GB-MYLANLABS-2019M1007404,MYLAN,,,,,M,Y,,,20190129,,OT,GB,GB,EFAVIRENZ.,Abortion spontaneous;Cleft lip and palate;Hydrops foetalis;Maternal drugs affecting foetus;Trisomy 18,158845191,OT,,,,,,,,,158845191,1,Product used for unknown indication
15885236,158852362,2,F,20181127,20190227,20190129,20190228,EXP,FR-AFSSAPS-NC20190054,FR-GILEAD-2019-0387183,GILEAD,,52,YR,A,M,Y,46,KG,20190228,,MD,FR,FR,EFAVIRENZ.,Muscular weakness;Paresis;Renal tubular disorder,158852362,OT,,,158852362,1,20180815,20181015,,,158852362,1,Hepatitis C
15889649,158896491,1,I,20060710,20190124,20190130,20190130,EXP,FR-EMA-DD-20190118-SINGH_N3-140615,FR-JNJFOC-20190132436,JANSSEN,,41,YR,A,M,Y,55,KG,20190130,,OT,FR,FR,SUSTIVA,Onychomadesis;Pruritus;Rash;Stevens-Johnson syndrome,158896491,LT,,,158896491,1,20060615,20060728,,,158896491,1,Product used for unknown indication
15893560,158935601,1,I,,20190123,20190131,20190131,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007790,BRISTOL MYERS SQUIBB,,46,YR,,M,Y,,,20190131,,MD,PT,PT,EFAVIRENZ.,Nephropathy toxic,158935601,OT,,,,,,,,,158935601,1,HIV infection
15897533,158975331,1,I,,20190130,20190131,20190131,EXP,,PT-009507513-1901PRT011858,MERCK,,43,YR,,M,Y,,,20190131,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Hepatitis C,158975331,OT,,,,,,,,,158975331,1,Chronic hepatitis C
15897679,158976791,1,I,,20180718,20190131,20190131,EXP,,ID-SUN PHARMACEUTICAL INDUSTRIES LTD-2018R1-180145,RANBAXY,"MOKOAGOW I, YUWAAFII M. GRAVES DISEASE AS MANIFESTATION OF IMMUNE RECONSTITUTION SYNDROME IN A PREGNANT PATIENT WITH HIV/AIDS RECEIVING ANTIRETROVIRAL THERAPY. ENDOCR PRACT. 2018;24 (SUPPL.1):270-271(ABSTRACT #1096)",36,YR,,F,Y,,,20190201,,OT,ID,ID,EFAVIRENZ.,Basedow's disease;Exposure during pregnancy,158976791,OT,,,,,,,,,158976791,1,HIV infection
15897762,158977621,1,I,20060413,20060516,20190201,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13380423,BRISTOL MYERS SQUIBB,,28,YR,,F,Y,65,KG,20190201,,CN,FR,FR,SUSTIVA,Pruritus;Rash maculo-papular;Toxic skin eruption,158977621,OT,,,158977621,1,20060403,20060413,,,158977621,1,HIV infection
15900709,159007091,1,I,201711,20190122,20190201,20190201,EXP,,PL-GILEAD-2019-0386699,GILEAD,,45,YR,A,M,Y,,,20190201,,MD,PL,PL,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Thrombocytopenia,159007091,DE,,,159007091,1,20171113,20171116,,,159007091,1,HIV infection
15900993,159009931,1,I,,20190118,20190201,20190201,EXP,,GB-GLAXOSMITHKLINE-GB2019GSK017750,GLAXOSMITHKLINE,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22,YR,,F,Y,,,20190201,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159009931,OT,,,,,,,,,159009931,1,HIV infection
15900994,159009941,1,I,,20190118,20190201,20190201,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2019GSK017750,VIIV,"AHMED N, FLAVELL S, FERNS B, FRAMPTON D, EDWARDS SG, MILLER RF ET AL.. DEVELOPMENT OF THE R263K MUTATION TO DOLUTEGRAVIR IN AN HIV-1 SUBTYPE D VIRUS HARBORING 3 CLASS- DRUG RESISTANCE. OFID. 2018;6 (1):329",22,YR,,F,Y,,,20190201,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159009941,OT,,,,,,,,,159009941,1,HIV infection
15902352,159023521,1,I,20060413,20060516,20190201,20190201,EXP,,FR-GILEAD-2006-0009601,GILEAD,,28,YR,A,F,Y,65,KG,20190201,,MD,FR,FR,SUSTIVA,Pruritus;Rash maculo-papular;Toxic skin eruption,159023521,OT,,,159023521,1,20060403,20060413,,,159023521,1,HIV infection
15903040,159030401,1,I,,20190121,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004927,AUROBINDO,,,,,,Y,,,20190202,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,159030401,OT,,,159030401,4,,200905,,,159030401,1,HIV infection
15903044,159030441,1,I,201102,20190121,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004928,AUROBINDO,,,,,,Y,,,20190202,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159030441,OT,,,,,,,,,159030441,1,HIV infection
15903045,159030451,1,I,,20190121,20190202,20190202,EXP,,ZA-AUROBINDO-AUR-APL-2019-004929,AUROBINDO,,,,,,Y,,,20190202,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159030451,DE,,,,,,,,,159030451,1,HIV infection
15903765,159037651,1,I,201011,20190121,20190203,20190203,EXP,,ZA-AUROBINDO-AUR-APL-2019-004930,AUROBINDO,,,,,,Y,,,20190204,,OT,ZA,ZA,EFAVIRENZ.,Drug resistance;Tuberculosis,159037651,OT,,,,,,,,,159037651,1,HIV infection
15903768,159037681,1,I,,20190121,20190203,20190203,EXP,,ZA-AUROBINDO-AUR-APL-2019-004931,AUROBINDO,,,,,,Y,,,20190204,,OT,ZA,ZA,EFAVIRENZ.,Disease recurrence;Drug resistance;Tuberculosis,159037681,OT,,,,,,,,,159037681,1,HIV infection
15903849,159038493,3,F,,20190207,20190204,20190213,EXP,,ZA-AUROBINDO-AUR-APL-2019-005752,AUROBINDO,,,,,,Y,,,20190213,,MD,ZA,ZA,Efavirenz+Emtricitabine+Tenofovir,Congenital acrochordon;Foetal exposure during pregnancy,159038493,CA,,,159038493,1,20180412,,,,159038493,1,HIV infection
15904994,159049941,1,I,20070106,20190123,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-007872,BRISTOL MYERS SQUIBB,,47,YR,,M,Y,,,20190204,,MD,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms;Eosinophilia;Eyelid oedema;Face oedema;Hepatitis;Lip oedema;Oral disorder;Rash maculo-papular,159049941,HO,,,159049941,1,20070103,20070108,,,159049941,1,Product used for unknown indication
15905632,159056321,1,I,20060318,20060613,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13412275,BRISTOL MYERS SQUIBB,,38,YR,,M,Y,,,20190204,,CN,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms,159056321,OT,,,159056321,1,20060225,20060329,,,159056321,1,Acquired immunodeficiency syndrome
15906784,159067841,1,I,20181215,20190124,20190204,20190204,EXP,,KE-GILEAD-2019-0387226,GILEAD,,66,YR,E,F,Y,54.6,KG,20190204,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,159067841,OT,,,159067841,1,20170515,20181215,,,159067841,1,Antiretroviral therapy
15907000,159070002,2,F,,20190214,20190204,20190221,EXP,,ZA-GILEAD-2019-0387924,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",35,YR,A,F,Y,,,20190221,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159070002,HO,,,,,,,,,159070002,1,HIV infection
15907173,159071732,2,F,,20190214,20190204,20190221,EXP,,ZA-GILEAD-2019-0387922,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS.. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",28,YR,A,F,Y,,,20190221,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159071732,OT,,,,,,,,,159071732,1,HIV infection
15907184,159071842,2,F,,20190214,20190204,20190221,EXP,,ZA-GILEAD-2019-0387923,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G.. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS.. 2019;NI:NI. DOI:DOI: 10.1097/QAD.0000000000002136",39,YR,A,F,Y,,,20190221,,OT,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159071842,OT,,,,,,,,,159071842,1,HIV infection
15907748,159077481,1,I,20060415,20190123,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-008096,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,64,KG,20190204,,MD,FR,FR,SUSTIVA,Cholestasis;Hyperlipidaemia;Hypertension;Renal infarct;Splenic infarction,159077481,LT,,,159077481,1,20040719,,,,159077481,1,Product used for unknown indication
15913221,159132212,2,F,20181029,20190204,20190204,20190208,EXP,NO-NOMAADVRE-RELISSO-2019-00071,NO-GILEAD-2019-0387532,GILEAD,,28,YR,A,F,Y,,,20190208,,MD,NO,NO,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,159132212,OT,,,159132212,2,20180827,20181028,,,159132212,1,Product used for unknown indication
15914632,159146321,1,I,20190111,,20190111,20190111,DIR,,,FDA-CTU,,25,YR,,M,N,,,20190111,N,PH,US,US,EFAVIRENZ.,Blood HIV RNA;Drug ineffective,,,159146321,HP,159146321,1,201804,201812,,,159146321,1,HIV infection
15916332,159163321,1,I,20040206,20060313,20190204,20190204,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13313473,BRISTOL MYERS SQUIBB,,35,YR,,M,Y,63,KG,20190204,,OT,FR,FR,SUSTIVA,Abdominal pain upper;Amylase increased;Cholelithiasis;Hyperbilirubinaemia;Jaundice;Lipase increased;Pancreatitis acute;Pancreatitis chronic;Vomiting,159163321,OT,,,159163321,1,20030514,20050629,,,159163321,1,HIV infection
15920383,159203831,1,I,,20190130,20190205,20190205,EXP,,CA-TEVA-2019-CA-1007031,TEVA,,52,YR,,M,Y,,,20190205,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,159203831,CA,,,,,,,,,159203831,1,HIV infection
15920654,159206541,1,I,,20190129,20190205,20190205,EXP,,GB-MYLANLABS-2019M1009673,MYLAN,,31,YR,,F,Y,,,20190205,,CN,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Premature delivery,159206541,OT,,,,,,,,,159206541,1,Product used for unknown indication
15923308,159233081,1,I,,20190128,20190206,20190206,EXP,,IN-HETERO CORPORATE-HET2019IN00110,HETERO,"SHAMANNA SURYANARAYANA BETTADPURA, MATTA KIRAN KUMAR AND HAMIDE ABDOUL. TRENDS IN CLINICAL CHARACTERISTICS AND SHORT-TERM OUTCOME OF HIV-INFECTED PATIENTS AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2018;17",,,A,,Y,,,20190206,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,159233081,OT,,,,,,,,,159233081,1,HIV infection
15923322,159233221,1,I,,20190128,20190206,20190206,EXP,,IN-HETERO CORPORATE-HET2019IN00132,HETERO,"SHAMANNA SURYANARAYANA BETTADPURA , MATTA KIRAN KUMAR AND HAMIDE ABDOUL. TRENDS IN CLINICAL CHARACTERISTICS AND SHORT-TERM OUTCOME OF HIV-INFECTED PATIENTS AT A TERTIARY CARE HOSPITAL IN SOUTH INDIA. JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE. 2018;17",,,A,,Y,,,20190206,,OT,IN,IN,EFAVIRENZ.,Stevens-Johnson syndrome,159233221,OT,,,,,,,,,159233221,1,HIV infection
15927122,159271221,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020678,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159271221,OT,,,,,,,,,159271221,1,HIV infection
15927124,159271241,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020678,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159271241,OT,,,,,,,,,159271241,1,HIV infection
15927250,159272501,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020733,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272501,OT,,,,,,,,,159272501,1,HIV infection
15927253,159272531,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020740,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272531,OT,,,,,,,,,159272531,1,HIV infection
15927265,159272651,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020733,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272651,OT,,,,,,,,,159272651,1,HIV infection
15927267,159272671,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020740,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159272671,OT,,,,,,,,,159272671,1,HIV infection
15927372,159273721,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020735,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273721,OT,,,,,,,,,159273721,1,HIV infection
15927374,159273741,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020741,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273741,OT,,,,,,,,,159273741,1,HIV infection
15927378,159273781,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020735,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273781,OT,,,,,,,,,159273781,1,HIV infection
15927380,159273801,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020741,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273801,OT,,,,,,,,,159273801,1,HIV infection
15927382,159273821,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020734,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273821,OT,,,,,,,,,159273821,1,HIV infection
15927384,159273841,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020751,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273841,OT,,,,,,,,,159273841,1,HIV infection
15927387,159273871,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020749,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273871,OT,,,,,,,,,159273871,1,HIV infection
15927389,159273891,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020750,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273891,OT,,,,,,,,,159273891,1,HIV infection
15927391,159273911,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020748,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273911,OT,,,,,,,,,159273911,1,HIV infection
15927393,159273931,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020734,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273931,OT,,,,,,,,,159273931,1,HIV infection
15927395,159273951,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020751,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273951,OT,,,,,,,,,159273951,1,HIV infection
15927397,159273971,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020750,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273971,OT,,,,,,,,,159273971,1,HIV infection
15927399,159273991,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020749,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159273991,OT,,,,,,,,,159273991,1,HIV infection
15927401,159274011,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020748,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159274011,OT,,,,,,,,,159274011,1,HIV infection
15927501,159275011,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020747,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275011,OT,,,,,,,,,159275011,1,HIV infection
15927503,159275031,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020746,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275031,OT,,,,,,,,,159275031,1,HIV infection
15927505,159275051,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020745,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275051,OT,,,,,,,,,159275051,1,HIV infection
15927507,159275071,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020744,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275071,OT,,,,,,,,,159275071,1,HIV infection
15927510,159275101,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020747,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275101,OT,,,,,,,,,159275101,1,HIV infection
15927512,159275121,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020746,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275121,OT,,,,,,,,,159275121,1,HIV infection
15927514,159275141,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020745,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275141,OT,,,,,,,,,159275141,1,HIV infection
15927516,159275161,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020744,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275161,OT,,,,,,,,,159275161,1,HIV infection
15927521,159275211,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020736,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275211,OT,,,,,,,,,159275211,1,HIV infection
15927523,159275231,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020739,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275231,OT,,,,,,,,,159275231,1,HIV infection
15927525,159275251,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020738,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275251,OT,,,,,,,,,159275251,1,HIV infection
15927527,159275271,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020737,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275271,OT,,,,,,,,,159275271,1,HIV infection
15927530,159275301,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020742,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275301,OT,,,,,,,,,159275301,1,HIV infection
15927532,159275321,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020736,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275321,OT,,,,,,,,,159275321,1,HIV infection
15927534,159275341,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020739,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275341,OT,,,,,,,,,159275341,1,HIV infection
15927537,159275371,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020737,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275371,OT,,,,,,,,,159275371,1,HIV infection
15927539,159275391,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020738,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275391,OT,,,,,,,,,159275391,1,HIV infection
15927541,159275411,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020742,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159275411,OT,,,,,,,,,159275411,1,HIV infection
15927675,159276751,1,I,,20190125,20190206,20190206,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK020743,VIIV,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159276751,OT,,,,,,,,,159276751,1,HIV infection
15927677,159276771,1,I,,20190125,20190206,20190206,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK020743,GLAXOSMITHKLINE,,,,A,,Y,,,20190206,,OT,CN,CN,EFAVIRENZ.,Drug resistance;Pathogen resistance;Viral mutation identified;Virologic failure,159276771,OT,,,,,,,,,159276771,1,HIV infection
15928564,159285641,1,I,20180627,20190201,20190206,20190206,EXP,,LS-PFIZER INC-2019051783,PFIZER,,39,YR,,M,Y,56.9,KG,20190206,,MD,LS,LS,EFAVIRENZ.,Altered state of consciousness;Condition aggravated;Hepatic failure;Liver function test increased;Meningitis;Musculoskeletal stiffness;Pyrexia;Renal failure;Sepsis,159285641,HO,,,159285641,1,20180905,20190115,,,159285641,1,Tuberculosis
15929817,159298173,3,F,,20190214,20190206,20190221,EXP,,ZA-GILEAD-2019-0387921,GILEAD,"COHEN K, VILJOEN C, NJUGUNA C, MAARTENS G. EMTRICITABINE-ASSOCIATED RED CELL APLASIA.. AIDS. 2019;UNK:UNK. DOI:10.1097/QAD.0000000000002136",28,YR,A,F,Y,,,20190221,,MD,ZA,ZA,EFAVIRENZ.,Aplasia pure red cell,159298173,OT,,,,,,,,,159298173,1,HIV infection
15931518,159315181,1,I,,20190204,20190207,20190207,EXP,,PHHY2019GR027932,SANDOZ,,74,YR,,M,Y,,,20190207,,OT,GR,GR,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Dehydration;Hypotension;Lactic acidosis;Mucosal dryness;Nausea;Oliguria;Pulmonary hilar enlargement;Skin turgor decreased;Tachypnoea;Vomiting,159315181,LT,,,,,,,,,159315181,1,Type 2 diabetes mellitus
15934528,159345281,1,I,,20190201,20190207,20190207,EXP,,FR-MYLANLABS-2019M1011151,MYLAN,,,,N,,Y,,,20190207,,MD,FR,FR,EFAVIRENZ.,Brain herniation;Foetal exposure during pregnancy;Spina bifida,159345281,DE,,,159345281,1,20050523,20050908,,,159345281,1,Product used for unknown indication
15934798,159347981,1,I,,20190201,20190207,20190207,EXP,,GB-GILEAD-2019-0389014,GILEAD,,,,,M,Y,,,20190207,,CN,GB,GB,EFAVIRENZ.,Cerebrovascular accident,159347981,HO,,,,,,,,,159347981,1,Product used for unknown indication
15935098,159350981,1,I,20060710,20190129,20190207,20190207,EXP,,FR-TEVA-2019-FR-1006548,TEVA,,41,YR,,M,Y,55,KG,20190208,,MD,FR,FR,SUSTIVA,Onychomadesis;Pruritus;Rash;Stevens-Johnson syndrome,159350981,LT,,,159350981,1,20060615,20060728,,,,,
15935686,159356861,1,I,,20190129,20190208,20190208,EXP,,ZA-GILEAD-2019-0389520,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159356861,OT,,,,,,,,,159356861,1,HIV infection
15935691,159356912,2,F,,20190129,20190208,20190321,EXP,,ZA-GILEAD-2019-0389519,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190321,,OT,ZA,ZA,EFAVIRENZ.,Stillbirth,159356912,OT,,,,,,,,,159356912,1,HIV infection
15935699,159356991,1,I,,20190129,20190208,20190208,EXP,,ZA-GILEAD-2019-0389522,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159356991,OT,,,,,,,,,159356991,1,HIV infection
15935700,159357001,1,I,,20190129,20190208,20190208,EXP,,ZA-GILEAD-2019-0389521,GILEAD,"CHANDIWANA, N., ET AL.. PREGNANCY OUTCOMES AMONG HIV-POSITIVE WOMEN ON DOLUTEGRAVIR VERSUS EFAVIRENZ-BASED ANTIRETROVIRAL THERAPY: WEEK 48 ANALYSIS OF THE ADVANCE TRIAL. CONFERENCE ABSTRACT FOR INTERNATIONAL AIDS SOCIETY. UNK;UNK:UNK",,,,F,Y,,,20190207,,OT,ZA,ZA,EFAVIRENZ.,Abortion spontaneous,159357001,OT,,,,,,,,,159357001,1,HIV infection
15937004,159370041,1,I,,20190131,20190208,20190208,EXP,,BR-009507513-1902BRA000593,MERCK,,,,,F,Y,,,20190208,,CN,BR,BR,EFAVIRENZ.,Abortion spontaneous;Drug interaction;Pregnancy with implant contraceptive;Unintended pregnancy,159370041,OT,,,,,,,,,159370041,1,Contraception
15944766,159447661,1,I,,20190206,20190211,20190211,EXP,,PT-ROCHE-2261940,ROCHE,MENDEZ J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP. 2019;:-.,43,YR,,M,Y,,,20190211,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Hepatitis C,159447661,OT,,,,,,,,,159447661,1,Chronic hepatitis C
15945854,159458541,1,I,,20190128,20190212,20190212,EXP,,PT-AUROBINDO-AUR-APL-2019-006869,AUROBINDO,MENDEZ J.. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP.. 2019,,,,,Y,,,20190212,,MD,PT,PT,EFAVIRENZ.,Drug ineffective;Hepatitis C,159458541,OT,,,,,,,,,159458541,1,Chronic hepatitis C
15947564,159475642,2,F,20180627,20190201,20190211,20190227,EXP,,LS-BAYER-2019-025145,BAYER,,38,YR,A,M,Y,56,KG,20190227,,CN,JP,LS,EFAVIRENZ.,Altered state of consciousness;Hepatic enzyme increased;Hepatic failure;Meningitis;Musculoskeletal stiffness;Off label use;Product use in unapproved indication;Pyrexia;Renal failure;Sepsis,159475642,HO,,,159475642,1,20180409,20180822,,,159475642,1,Tuberculosis
15949431,159494311,1,I,20060719,20190207,20190212,20190212,EXP,,PHHY2019FR030552,SANDOZ,,41,YR,,F,Y,,,20190212,,OT,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159494311,HO,,,159494311,1,20060717,20060721,,,159494311,1,Depression
15950518,159505184,4,F,2014,20190307,20190211,20190313,EXP,,ES-MYLANLABS-2019M1011377,MYLAN,"BRAVO I, ALVAREZ H, MARINO A, CLOTET B, MOLTO J.. RECURRENT CORONARY DISEASE IN HIV-INFECTED PATIENTS: ROLE OF DRUG?DRUG INTERACTIONS. BR. J. CLIN. PHARMACOL.. 2018;84 (7):1617-1619",39,YR,,M,Y,,,20190313,,MD,ES,ES,EFAVIRENZ.,Acute coronary syndrome;Acute myocardial infarction;Chest pain;Drug interaction;Vascular stent thrombosis,159505184,OT,,,159505184,1,2012,,,,159505184,1,HIV infection
15953624,159536241,1,I,,20190207,20190212,20190212,EXP,,US-GILEAD-2019-0389881,GILEAD,,,,,M,Y,,,20190212,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Muscle disorder;Wheelchair user,159536241,DS,,,159536241,1,2010,,,,159536241,1,HIV infection
15954199,159541991,1,I,20060719,20190207,20190212,20190212,EXP,FR-EMA-20130709-MMEVHUMANWT-104720368,FR-GILEAD-2019-0390071,GILEAD,,41,YR,A,F,Y,,,20190212,,MD,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159541991,HO,,,159541991,1,20060713,20060721,,,159541991,1,HIV infection
15954282,159542821,1,I,,20190205,20190212,20190212,EXP,,GB-MYLANLABS-2019M1011884,MYLAN,"WOODCOCK H, NELSON M.. BURKITT^S NON-HODGKINS LYMPHOMA PRESENTING AS FACIAL NERVE PALSY IN HIVPOSITIVE PATIENTS.. INTERNATIONAL.. 2011;22 (2):112-114",55,YR,,M,Y,,,20190212,,OT,GB,GB,EFAVIRENZ.,Pancytopenia;Toxicity to various agents,159542821,OT,,,,,,,,,159542821,1,HIV infection
15957947,159579471,1,I,20060719,20190204,20190213,20190213,EXP,FR-EMA-20130709-MMEVHUMANWT-104720368,FR-ELI_LILLY_AND_COMPANY-FR201902001668,ELI LILLY AND CO,,41,YR,,F,Y,,,20190213,,CN,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159579471,HO,,,159579471,1,20060717,20060721,,,159579471,1,Depression
15959482,159594821,1,I,20060719,20190204,20190214,20190214,EXP,,FR-AUROBINDO-AUR-APL-2019-008074,AUROBINDO,,,,,,Y,,,20190214,,OT,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159594821,HO,,,159594821,1,20060717,20060721,,,159594821,1,Depression
15960563,159605632,2,F,,20190214,20190214,20190228,EXP,,GR-AUROBINDO-AUR-APL-2011-00475,AUROBINDO,,,,,,Y,,,20190228,,MD,GR,GR,EFAVIRENZ.,Abdominal pain;Acute kidney injury;Dehydration;Hypotension;Lactic acidosis;Mucosal dryness;Nausea;Oliguria;Pulmonary hilar enlargement;Skin turgor decreased;Tachypnoea;Vomiting,159605632,HO,,,,,,,,,159605632,1,Type 2 diabetes mellitus
15962439,159624395,5,F,20181001,20190304,20190214,20190308,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2018GSK236781,VIIV,,,,,,Y,,,20190308,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Meningomyelocele,159624395,DE,,,159624395,1,20170330,,,,159624395,1,HIV infection
15962440,159624405,5,F,20181001,20190304,20190214,20190308,EXP,,BW-GLAXOSMITHKLINE-BW2018GSK236781,GLAXOSMITHKLINE,,,,,,Y,,,20190308,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Meningomyelocele,159624405,OT,,,159624405,1,20170330,,,,159624405,1,HIV infection
15962868,159628682,2,F,201509,20190215,20190214,20190221,EXP,,CN-PFIZER INC-2019061812,PFIZER,"MIN, H.. REMISSION OF HIV-RELATED NA?VE AND HIGH-RISK BURKITT^S LYMPHOMA TREATED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS CART.. STEM CELL RESEARCH + THERAPY. 2018;9(1):353;10.1186/S13287-018-1089-5",27,YR,,M,Y,,,20190221,,OT,CN,CN,EFAVIRENZ.,Agranulocytosis;Bone marrow failure;Pneumonia;Staphylococcal sepsis,159628682,OT,,,159628682,1,20150921,20150923,,,159628682,1,Burkitt's lymphoma stage IV
15963115,159631151,1,I,,20190207,20190214,20190214,EXP,,US-GILEAD-2019-0390611,GILEAD,,,,A,M,Y,,,20190214,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Amnesia;Unevaluable event,159631151,HO,,,,,,,,,159631151,1,HIV infection
15964658,159646581,1,I,,20190131,20190215,20190215,EXP,,US-MACLEODS PHARMACEUTICALS US LTD-MAC2019020010,MACLEODS,,,,,,Y,,,20190215,,CN,US,UG,"LAMIVUDINE, EFAVIRENZ + TENOFOVIR",Foetal exposure during pregnancy;Foot deformity;Talipes,159646581,CA,,,159646581,1,20180521,,,,159646581,1,HIV infection
15965212,159652121,1,I,,20190205,20190215,20190215,EXP,,PT-009507513-1902PRT002804,MERCK,,48,YR,,M,Y,,,20190215,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction,159652121,OT,,,,,,,,,159652121,1,Hepatitis C
15965372,159653721,1,I,,20190205,20190215,20190215,EXP,,PT-009507513-1902PRT002808,MERCK,,42,YR,,M,Y,,,20190215,,MD,PT,PT,EFAVIRENZ.,Death,159653721,DE,,,,,,,,,159653721,1,Hepatitis C
15965660,159656601,1,I,,20190204,20190215,20190215,EXP,,GB-AUROBINDO-AUR-APL-2019-007759,AUROBINDO,,,,,,Y,,,20190215,,OT,GB,GB,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,159656601,OT,,,,,,,,,159656601,1,HIV infection
15965687,159656871,1,I,,20190205,20190215,20190215,EXP,,PT-009507513-1902PRT002774,MERCK,,59,YR,,M,Y,,,20190215,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,159656871,DE,,,,,,,,,159656871,1,Hepatitis C
15966138,159661382,2,F,,20190311,20190215,20190321,EXP,,PT-009507513-1902PRT002788,MERCK,,43,YR,,M,Y,,,20190321,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,159661382,OT,,,,,,,,,159661382,1,Hepatitis C
15969321,159693211,1,I,,20171218,20190215,20190215,EXP,,FR-LEO PHARMA-306883,LEO PHARM,,37,YR,,F,Y,,,20190215,,MD,FR,FR,SUSTIVA,Headache;Hypertension;Maternal exposure during pregnancy;Metrorrhagia;Pre-eclampsia,159693211,HO,,,159693211,5,20150608,20150608,,,159693211,1,Product used for unknown indication
15973979,159739791,1,I,20060717,20060818,20190217,20190217,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13482070,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,,,20190217,,CN,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159739791,HO,,,159739791,1,20060713,20060721,,,159739791,1,HIV infection
15978336,159783361,1,I,20060719,20190211,20190219,20190219,EXP,FR-EMA-20130709-MMEVHUMANWT-104720368,FR-TEVA-2019-FR-1012690,TEVA,,41,YR,,F,Y,,,20190219,,MD,FR,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159783361,HO,,,159783361,1,20060717,20060721,,,159783361,1,Depression
15978748,159787481,1,I,,20190213,20190219,20190219,EXP,,IN-GLAXOSMITHKLINE-IN2019GSK028835,GLAXOSMITHKLINE,,72,YR,,M,Y,,,20190219,,MD,IN,IN,EFAVIRENZ.,Arthralgia;Femoral neck fracture;Hypokinesia;Insomnia;Movement disorder,159787481,OT,,,,,,,,,159787481,1,HIV infection
15978751,159787511,1,I,,20190213,20190219,20190219,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2019GSK028835,VIIV,,72,YR,,M,Y,,,20190219,,MD,IN,IN,EFAVIRENZ.,Arthralgia;Femoral neck fracture;Hypokinesia;Insomnia;Movement disorder,159787511,OT,,,,,,,,,159787511,1,HIV infection
15980310,159803103,3,F,,20190213,20190219,20190219,EXP,,PHHY2019FR036384,SANDOZ,,37,YR,,F,Y,,,20190219,,OT,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,159803103,HO,,,,,,,,,159803103,1,Product used for unknown indication
15982257,159822572,2,F,20030725,20190305,20190219,20190306,EXP,,FR-GILEAD-2003-06494,GILEAD,,43,YR,A,F,Y,74,KG,20190306,,OT,FR,FR,SUSTIVA,Aggression;Ascites;Hepatic necrosis;Hepatitis A;Jaundice;Peritoneal haematoma;Somnolence;Vomiting,159822572,HO,,,159822572,1,20030412,20030728,,,159822572,1,HIV infection
15982566,159825661,1,I,20060602,20190212,20190219,20190219,EXP,,CA-ABBVIE-19P-028-2666991-00,ABBVIE,"HARRIS M, LARSEN G, MONTANER J. EXACERBATION OF DEPRESSION ASSOCIATED WITH STARTING RALTEGRAVIR: A REPORT OF FOUR CASES. AIDS. 2008;22 (14):1890-1892.",44,YR,,M,Y,,,20190219,,OT,COUNTRY NOT SPECIFIED,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,159825661,HO,,,159825661,2,20060602,20070522,,,159825661,1,HIV infection
15982810,159828101,1,I,20181022,20190213,20190219,20190219,EXP,,GB-GILEAD-2019-0391318,GILEAD,,35,YR,A,F,Y,,,20190219,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,159828101,OT,,,,,,,,,159828101,1,HIV infection
15982971,159829711,1,I,,20190206,20190219,20190219,EXP,,US-GILEAD-2019-0391837,GILEAD,,63,YR,A,M,Y,,,20190219,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bronchitis;Leukaemia;Malaise,159829711,OT,,,,,,,,,159829711,1,Product used for unknown indication
15983366,159833661,1,I,,20190206,20190220,20190220,EXP,,IT-AUROBINDO-AUR-APL-2019-008587,AUROBINDO,,,,,,Y,,,20190220,,OT,IT,IT,EFAVIRENZ.,Drug interaction;Virologic failure,159833661,OT,,,,,,,,,159833661,1,HIV infection
15984450,159844501,1,I,20060719,20190208,20190220,20190220,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2019RR-199626,RANBAXY,,41,YR,,F,Y,,,20190220,,OT,GB,FR,SUSTIVA,Depression;Headache;Pyrexia;Rash scarlatiniform;Vulvovaginal candidiasis,159844501,HO,,,159844501,1,20060717,20060721,,,159844501,1,Depression
15984880,159848801,1,I,,20190212,20190220,20190220,EXP,,FR-BAUSCH-BL-2019-004699,BAUSCH AND LOMB,,37,YR,,F,Y,,,20190220,,MD,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,159848801,HO,,,159848801,4,20150608,20150608,,,159848801,1,Product used for unknown indication
15985003,159850031,1,I,,20190215,20190220,20190220,EXP,,BW-STRIDES ARCOLAB LIMITED-2019SP001577,STRIDES,,,,N,,Y,,,20190220,,OT,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele,159850031,CA,,,,,,,,,159850031,1,Product used for unknown indication
15985004,159850041,1,I,,20190215,20190220,20190220,EXP,,BW-STRIDES ARCOLAB LIMITED-2019SP001576,STRIDES,,42,YR,,F,Y,,,20190220,,OT,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,159850041,OT,,,,,,,,,159850041,1,Product used for unknown indication
15987738,159877381,1,I,,20190212,20190220,20190220,EXP,,GB-GILEAD-2019-0390776,GILEAD,,53,YR,A,M,Y,,,20190220,,CN,GB,GB,EFAVIRENZ.,Arthropathy,159877381,OT,,,,,,,,,159877381,1,Product used for unknown indication
15989803,159898031,1,I,,20190214,20190221,20190221,EXP,,BW-MYLANLABS-2019M1015918,MYLAN,,,,N,,Y,,,20190221,,OT,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele,159898031,CA,,,,,,,,,159898031,1,Product used for unknown indication
15990442,159904421,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016125,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",35,YR,,F,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159904421,OT,,,,,,,,,159904421,1,HIV infection
15990444,159904441,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016207,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",60,YR,,M,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159904441,OT,,,,,,,,,159904441,1,HIV infection
15990529,159905291,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016255,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",51,YR,,F,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159905291,OT,,,,,,,,,159905291,1,HIV infection
15990788,159907881,1,I,,20190215,20190221,20190221,EXP,,CA-009507513-1902CAN006436,MERCK,,54,YR,,M,Y,,,20190221,,OT,CA,CA,EFAVIRENZ.,Depression;Drug interaction,159907881,OT,,,,,,,,,159907881,1,Product used for unknown indication
15990897,159908972,2,F,20181001,20190213,20190221,20190222,EXP,,BY-009507513-1902BLR005586,MERCK,,59,YR,,F,Y,42.5,KG,20190222,,CN,JP,US,EFAVIRENZ.,Hepatic enzyme increased,159908972,OT,,,159908972,1,20180801,20181123,,,159908972,1,Tuberculosis
15991009,159910091,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016134,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",37,YR,,M,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159910091,OT,,,,,,,,,159910091,1,HIV infection
15991150,159911501,1,I,,20190219,20190221,20190221,EXP,,PT-GILEAD-2019-0391916,GILEAD,,48,YR,A,M,Y,,,20190221,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction,159911501,DE,,,,,,,,,159911501,1,Hepatitis C
15991981,159919812,2,F,,20190307,20190221,20190312,EXP,,GB-MYLANLABS-2019M1015365,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,159919812,OT,,,,,,,,,159919812,1,HIV infection
15992613,159926131,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016265,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",47,YR,,M,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159926131,OT,,,,,,,,,159926131,1,HIV infection
15992639,159926391,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016272,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",51,YR,,M,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159926391,OT,,,,,,,,,159926391,1,HIV infection
15992731,159927311,1,I,,20190213,20190221,20190221,EXP,,FR-MYLANLABS-2019M1016122,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEM-BIOL-DRUG-DES 2019;93(1):50-59.",45,YR,,M,Y,,,20190221,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,159927311,OT,,,,,,,,,159927311,1,HIV infection
15994788,159947881,1,I,20181001,20190214,20190222,20190222,EXP,,BW-HETERO CORPORATE-HET2019BW00182,HETERO,,0,DY,,,Y,,,20190222,,OT,BW,BW,EFAVIRENZ.,Death;Foetal exposure during pregnancy;Meningomyelocele,159947881,CA,,,159947881,1,,20181001,,,159947881,1,HIV infection
15996615,159966151,1,I,,20190219,20190222,20190222,EXP,,PT-GILEAD-2019-0392499,GILEAD,,42,YR,A,M,Y,,,20190222,,MD,PT,PT,EFAVIRENZ.,Death,159966151,DE,,,,,,,,,159966151,1,Hepatitis C
15996748,159967481,1,I,,20190218,20190222,20190222,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-017670,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190222,,CN,US,US,SUSTIVA,Pre-existing condition improved;Therapeutic response unexpected,,,,,,,,,,,159967481,1,Product used for unknown indication
15998256,159982561,1,I,,20190215,20190223,20190223,EXP,,CA-009507513-1902CAN006457,MERCK,,54,YR,,M,Y,,,20190223,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,159982561,OT,,,,,,,,,159982561,1,HIV infection
15998853,159988531,1,I,,20190215,20190223,20190223,EXP,,CA-009507513-1902CAN006364,MERCK,,52,YR,,M,Y,,,20190223,,OT,CA,CA,EFAVIRENZ.,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,159988531,OT,,,,,,,,,159988531,1,HIV infection
15998972,159989721,1,I,,20190219,20190223,20190223,EXP,,PHHY2019PT042426,SANDOZ,,42,YR,,M,Y,,,20190224,,OT,PT,PT,EFAVIRENZ.,Death,159989721,DE,,,,,,,,,159989721,1,HIV test positive
16001877,160018771,1,I,,20190219,20190225,20190225,EXP,,PHHY2019PT042241,SANDOZ,,59,YR,,M,Y,,,20190225,,OT,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160018771,DE,,,,,,,,,160018771,1,HIV test positive
16002089,160020891,1,I,,20190219,20190225,20190225,EXP,,PT-GILEAD-2019-0392459,GILEAD,,59,YR,A,M,Y,,,20190225,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160020891,OT,,,,,,,,,160020891,1,Hepatitis C
16004905,160049051,1,I,20181001,20190214,20190226,20190226,EXP,,BW-HETERO CORPORATE-HET2019BW00183,HETERO,,42,YR,,F,Y,,,20190226,,OT,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160049051,OT,,,,,,,,,160049051,1,HIV infection
16006520,160065201,1,I,,20190215,20190226,20190226,EXP,,GB-MYLANLABS-2019M1016072,MYLAN,,,,A,,Y,,,20190226,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Treatment noncompliance;Virologic failure,160065201,OT,,,,,,,,,160065201,1,HIV infection
16009753,160097533,3,F,20181001,20190304,20190225,20190313,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-017261,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20190313,,OT,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,160097533,OT,,,,,,,,,160097533,1,Antiretroviral therapy
16010009,160100091,1,I,,20190213,20190227,20190227,EXP,,CA-AUROBINDO-AUR-APL-2019-010050,AUROBINDO,,,,,,Y,,,20190227,,CN,CA,CA,EFAVIRENZ.,Aphonia;Dysphonia;Eczema;Hepatitis B;Intervertebral disc protrusion;Lumbar spinal stenosis;Nasopharyngitis;Nausea;Pulmonary pain;Sleep disorder;Syphilis,160100091,OT,,,,,,,,,160100091,1,HIV infection
16010060,160100601,1,I,,20190225,20190227,20190227,EXP,,PT-ROCHE-2272339,ROCHE,,59,YR,,M,Y,,,20190227,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160100601,DE,,,,,,,,,160100601,1,Hepatitis C
16010075,160100751,1,I,,20190225,20190227,20190227,EXP,,PT-ROCHE-2272208,ROCHE,,42,YR,,M,Y,,,20190227,,MD,PT,PT,EFAVIRENZ.,Death,160100751,DE,,,,,,,,,160100751,1,Hepatitis C
16011638,160116382,2,F,,20190311,20190227,20190315,EXP,,PT-ROCHE-2272243,ROCHE,MENDEZ J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP. 2019;:-.,43,YR,,M,Y,,,20190315,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160116382,OT,,,,,,,,,160116382,1,Hepatitis C
16012986,160129861,1,I,,20190225,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018226,MYLAN,,,,A,,Y,,,20190227,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160129861,OT,,,,,,,,,160129861,1,HIV infection
16012988,160129881,1,I,,20190225,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018187,MYLAN,,,,A,,Y,,,20190227,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160129881,OT,,,,,,,,,160129881,1,HIV infection
16013050,160130501,1,I,,20190225,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018279,MYLAN,,,,A,,Y,,,20190227,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160130501,OT,,,,,,,,,160130501,1,HIV infection
16013410,160134101,1,I,,20190225,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018191,MYLAN,,,,A,,Y,,,20190227,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160134101,OT,,,,,,,,,160134101,1,HIV infection
16014594,160145941,1,I,,20190225,20190227,20190227,EXP,,GB-MYLANLABS-2019M1018245,MYLAN,,,,A,F,Y,,,20190227,,MD,GB,GB,SUSTIVA,Maternal exposure during pregnancy;Treatment noncompliance;Virologic failure,160145941,OT,,,,,,,,,160145941,1,HIV infection
16015501,160155011,1,I,,20190225,20190228,20190228,EXP,,PT-ROCHE-2272385,ROCHE,,48,YR,,M,Y,,,20190228,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction,160155011,DE,,,,,,,,,160155011,1,Hepatitis C
16018750,160187501,1,I,,20190225,20190228,20190228,EXP,,GB-MYLANLABS-2019M1018254,MYLAN,,,,A,,Y,,,20190228,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160187501,OT,,,,,,,,,160187501,1,HIV infection
16019605,160196051,1,I,,20190225,20190228,20190228,EXP,,GB-MYLANLABS-2019M1018255,MYLAN,,,,A,,Y,,,20190228,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160196051,OT,,,,,,,,,160196051,1,HIV infection
16020890,160208902,2,F,,20190301,20190301,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-010743,AUROBINDO,,,,,,Y,,,20190316,,OT,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,160208902,OT,,,,,,,,,160208902,1,HIV infection
16020953,160209531,1,I,,20190214,20190301,20190301,EXP,,CA-AUROBINDO-AUR-APL-2019-010724,AUROBINDO,,,,,,Y,,,20190301,,OT,CA,CA,EFAVIRENZ.,HIV viraemia;Nephropathy toxic;Therapeutic response decreased,160209531,OT,,,,,,,,,160209531,1,HIV infection
16021250,160212501,1,I,,20190215,20190301,20190301,EXP,,BW-CIPLA LTD.-2019BW01100,CIPLA,,,,,,Y,,,20190301,,OT,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele,160212501,OT,,,,,,,,,,,
16021279,160212792,2,F,,20190215,20190301,20190301,EXP,,BW-CIPLA LTD.-2019BW01099,CIPLA,,,,,,Y,,,20190301,,OT,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,160212792,OT,,,,,,,,,160212792,1,Product used for unknown indication
16022383,160223831,1,I,,20190214,20190301,20190301,EXP,,BW-AUROBINDO-AUR-APL-2019-009434,AUROBINDO,,,,,,Y,,,20190301,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Meningomyelocele;Stillbirth,160223831,OT,,,,,,,,,160223831,1,Product used for unknown indication
16022512,160225121,1,I,,20190214,20190301,20190301,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,,,,,,Y,,,20190301,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,160225121,OT,,,,,,,,,160225121,1,HIV infection
16025359,160253591,1,I,,20190225,20190301,20190301,EXP,,BR-GILEAD-2019-0393897,GILEAD,"NUNES DE ALMEIDA B, CAMPELLO VIEIRA M, RAMOS DAL PIAZ M, SILVA CUNHA M, COMPART HEMERLY M, ARA?JO DE FREITAS P, SIM?ES MOREIRA M, MACHADO LUCHI W. FANCONI SYNDROME AND BONE FRACTURES RELATED TO TENOFOVIR USE. 29TH BRAZILIAN CONGRESS OF NEPHROLOGY HELD JOINTLY WITH THE 17TH BRAZILIAN CONGR. 2019;UNK:UNK",62,YR,A,F,Y,,,20190301,,OT,BR,BR,EFAVIRENZ.;EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE/EFAVIRENZ,Acute kidney injury;Bone lesion;Fanconi syndrome acquired;Hyperparathyroidism secondary;Vitamin D deficiency,160253591,OT,,,160253591,1,2014,,,,160253591,1,HIV infection
16025998,160259982,2,F,,20190307,20190302,20190320,EXP,,PT-AUROBINDO-AUR-APL-2019-011083,AUROBINDO,"MENDEZ,J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP. 2019;UNK:UNK",,,,,Y,,,20190320,,MD,PT,PT,Efavirenz Film Coated Tablets,Hepatitis C;Treatment failure,160259982,OT,,,,,,,,,160259982,1,Hepatitis C
16032364,160323641,1,I,20110825,20181217,20190304,20190304,EXP,,PHHY2018FR195300,SANDOZ,,51,YR,,M,Y,,,20190305,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160323641,OT,,,,,,,,,160323641,1,HIV infection
16032510,160325101,1,I,,20190220,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019030,BRISTOL MYERS SQUIBB,,48,YR,,M,Y,,,20190304,,MD,PT,PT,EFAVIRENZ.,Acute myocardial infarction,160325101,DE,,,,,,,,,160325101,1,HIV infection
16032534,160325341,1,I,,20190220,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019017,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,,,20190304,,MD,PT,PT,EFAVIRENZ.,Death,160325341,OT,,,,,,,,,160325341,1,HIV test positive
16032574,160325741,1,I,,20190220,20190304,20190304,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019013,BRISTOL MYERS SQUIBB,,59,YR,,M,Y,,,20190304,,MD,PT,PT,EFAVIRENZ.,Hepatocellular carcinoma,160325741,DE,,,,,,,,,160325741,1,HIV test positive
16035546,160355461,1,I,,20190225,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018688,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160355461,OT,,,,,,,,,160355461,1,HIV infection
16035702,160357021,1,I,,20190225,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018778,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160357021,OT,,,,,,,,,160357021,1,HIV infection
16036848,160368481,1,I,20180525,20190227,20190305,20190305,EXP,,PHHY2019KZ047903,NOVARTIS,,31,YR,,M,Y,,,20190305,,CN,US,KZ,EFAVIRENZ.,Blood glucose increased;Blood pressure decreased;Cardiopulmonary failure;Chronic hepatitis;Diabetic ketoacidotic hyperglycaemic coma;Gallbladder disorder;Generalised tonic-clonic seizure;Haemoglobin decreased;Hepatic cyst;Incorrect product administration duration;Loss of consciousness;Overdose;Platelet count decreased;Sinus tachycardia,160368481,OT,,,160368481,1,20180525,20190209,,,160368481,1,Pulmonary tuberculosis
16037477,160374771,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018805,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160374771,OT,,,,,,,,,160374771,1,HIV infection
16037732,160377321,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018882,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160377321,OT,,,,,,,,,160377321,1,HIV infection
16037738,160377381,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018883,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160377381,OT,,,,,,,,,160377381,1,HIV infection
16037815,160378151,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018941,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160378151,OT,,,,,,,,,160378151,1,HIV infection
16037817,160378171,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1018934,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160378171,OT,,,,,,,,,160378171,1,HIV infection
16037903,160379031,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019188,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160379031,OT,,,,,,,,,160379031,1,HIV infection
16038062,160380621,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019113,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160380621,OT,,,,,,,,,160380621,1,HIV infection
16038135,160381351,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019050,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160381351,OT,,,,,,,,,160381351,1,HIV infection
16038219,160382191,1,I,,20190226,20190305,20190305,EXP,,GB-MYLANLABS-2019M1019057,MYLAN,,,,A,,Y,,,20190305,,MD,GB,GB,SUSTIVA,Virologic failure,160382191,OT,,,,,,,,,160382191,1,HIV infection
16038861,160388611,1,I,20110825,20181217,20190306,20190306,EXP,,PHHY2018FR195309,SANDOZ,,45,YR,,M,Y,,,20190306,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160388611,OT,,,,,,,,,160388611,1,HIV infection
16039616,160396161,1,I,,20190222,20190306,20190306,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019394,BRISTOL MYERS SQUIBB,,53,YR,,M,Y,,,20190306,,CN,GB,GB,EFAVIRENZ.,Arthropathy,160396161,OT,,,,,,,,,160396161,1,Product used for unknown indication
16040438,160404381,1,I,,20190226,20190306,20190306,EXP,,GB-MYLANLABS-2019M1019075,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160404381,OT,,,,,,,,,160404381,1,HIV infection
16040439,160404391,1,I,,20190226,20190306,20190306,EXP,,GB-MYLANLABS-2019M1019079,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160404391,OT,,,,,,,,,160404391,1,HIV infection
16040861,160408611,1,I,,20190222,20190306,20190306,PER,,US-GILEAD-2019-0392959,GILEAD,,60,YR,A,M,Y,,,20190306,,OT,US,US,SUSTIVA,Drug resistance,160408611,OT,,,,,,,,,160408611,1,HIV infection
16043054,160430541,1,I,201808,20190301,20190306,20190306,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2019GSK039654,VIIV,,,,,F,Y,,,20190306,,MD,UG,UG,EFAVIRENZ.,Suicidal ideation,160430541,OT,,,160430541,1,20180328,20180403,,,160430541,1,HIV infection
16043220,160432201,1,I,2018,20181212,20190306,20190306,EXP,,ZA-MYLANLABS-2018M1093637,MYLAN,,,,,M,Y,3.84,KG,20190306,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Strabismus congenital,160432201,CA,,,160432201,1,20180309,,,,160432201,1,HIV infection
16043405,160434051,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020563,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal impairment;Virologic failure,160434051,OT,,,,,,,,,160434051,1,HIV infection
16043710,160437101,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020547,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,SUSTIVA,Virologic failure,160437101,OT,,,,,,,,,160437101,1,HIV infection
16044070,160440701,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020520,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160440701,OT,,,,,,,,,160440701,1,HIV infection
16044074,160440741,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020536,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lipids increased;Nervous system disorder;Virologic failure,160440741,OT,,,,,,,,,160440741,1,HIV infection
16044093,160440931,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020518,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,SUSTIVA,Virologic failure,160440931,OT,,,,,,,,,160440931,1,HIV infection
16044317,160443171,1,I,,20190301,20190306,20190306,EXP,,GB-MYLANLABS-2019M1020577,MYLAN,,,,A,,Y,,,20190306,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160443171,OT,,,,,,,,,160443171,1,HIV infection
16045303,160453031,1,I,,20190220,20190307,20190307,EXP,,FR-TEVA-2019-FR-1020967,TEVA,,37,YR,,F,Y,,,20190307,,MD,FR,FR,SUSTIVA,Headache;Hypertension;Metrorrhagia;Pre-eclampsia,160453031,HO,,,160453031,6,20150608,20150608,,,160453031,1,Product used for unknown indication
16049483,160494831,1,I,,20190304,20190307,20190307,EXP,,GB-GILEAD-2019-0395129,GILEAD,,,,,M,Y,,,20190307,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Perineal abscess,160494831,HO,,,,,,,,,160494831,1,Product used for unknown indication
16051090,160510901,1,I,,20190222,20190308,20190308,EXP,,GB-AUROBINDO-AUR-APL-2019-011935,AUROBINDO,,,,,,Y,,,20190308,,CN,GB,GB,EFAVIRENZ.,Arthropathy,160510901,OT,,,,,,,,,160510901,1,Product used for unknown indication
16051353,160513533,3,F,20110825,20190322,20190308,20190330,EXP,,FR-AUROBINDO-AUR-APL-2018-062564,AUROBINDO,,,,,,Y,,,20190330,,OT,FR,FR,Efavirenz Film Coated Tablets,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160513533,OT,,,,,,,,,160513533,1,HIV infection
16051764,160517641,1,I,,20190226,20190308,20190308,PER,,US-CELGENEUS-USA-20190209210,CELGENE,"ZARBAFIAN M, COTE B, RICHER V. TREATMENT OF MODERATE TO SEVERE PSORIASIS WITH APREMILAST OVER TWO YEARS IN THE CONTEXT OF LONG-TERM TREATED HIV INFECTION: A CASE REPORT. 77TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGY (AAD). 2019 MAR 01;.",,,,M,Y,,,20190308,,OT,US,US,EFAVIRENZ.,Diarrhoea,,,,,,,,,,,160517641,1,Psoriasis
16052306,160523061,1,I,,20190222,20190308,20190308,EXP,,US-GLAXOSMITHKLINE-US2019040980,GLAXOSMITHKLINE,,,,,M,Y,,,20190308,,OT,US,US,SUSTIVA,Drug resistance,160523061,OT,,,,,,,,,160523061,1,HIV infection
16052308,160523081,1,I,,20190222,20190308,20190308,EXP,,US-VIIV HEALTHCARE LIMITED-US2019040980,VIIV,,,,,M,Y,,,20190308,,OT,US,US,SUSTIVA,Drug resistance,160523081,OT,,,,,,,,,160523081,1,HIV infection
16054130,160541301,1,I,20180503,20190227,20190308,20190308,EXP,,CN-GILEAD-2019-0393740,GILEAD,,59,YR,A,M,Y,,,20190308,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160541301,HO,,,160541301,1,20180410,,,,160541301,1,HIV infection
16057849,160578492,2,F,2019,20190321,20190311,20190329,EXP,,BR-MYLANLABS-2019M1021741,MYLAN,,,,,M,Y,2.37,KG,20190329,,OT,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Hydrocele;Patent ductus arteriosus;Pericardial effusion,160578492,OT,,,160578492,1,20150815,,,,160578492,1,HIV infection
16062068,160620681,1,I,20190212,,20190212,20190212,DIR,,,FDA-CTU,,69,YR,,M,N,,,20190212,N,PH,US,US,EFAVIRENZ TAB,Anal cancer,,,160620681,HP,160620681,1,20160422,,,,160620681,1,HIV infection
16062808,160628081,1,I,,20190225,20190312,20190312,EXP,,GB-SEBELA IRELAND LIMITED-2019SEB00057,SEBELA,"COCKBAIN BC, PERIS BM, ABBARA A, SO CW, COOKE G. DISSEMINATED CMV INFECTION AND HLH IN A PATIENT WITH WELL-CONTROLLED HIV AND ULCERATIVE COLITIS. BMJ CASE REP. 2019;12(2)",50,YR,,M,Y,,,20190312,,OT,GB,GB,TENOFOVIR/EFAVIRENZ/EMTRICITABINE,Cytomegalovirus infection;Haemophagocytic lymphohistiocytosis;Immunosuppression;Pancytopenia,160628081,OT,,,,,,,,,160628081,1,Colitis ulcerative
16063329,160633291,1,I,,20190305,20190312,20190312,EXP,,GB-MYLANLABS-2019M1021748,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160633291,OT,,,,,,,,,160633291,1,HIV infection
16064184,160641842,2,F,,20190325,20190312,20190330,EXP,,PHHY2018IT041063,SANDOZ,,17,YR,,F,Y,,,20190330,,OT,IT,IT,EFAVIRENZ.,Drug resistance;Gastrointestinal disorder;Inappropriate schedule of product administration;Pathogen resistance;Product use issue;Viral mutation identified,160641842,OT,,,,,,,,,160641842,1,HIV infection
16064283,160642831,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022445,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastrointestinal disorder;Lipids increased;Virologic failure,160642831,OT,,,,,,,,,160642831,1,HIV infection
16064290,160642901,1,I,,20190307,20190312,20190312,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2019044390,VIIV,GERHARDY B. AN ATYPICAL PNEUMONIA. RESPIROLOGY CASE REPORTS. 2019;7(3):ARTICLE NUMBER E00407. DOI: 10.1002/RCR2.407.,70,YR,,F,Y,,,20190312,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Haemoglobin decreased;Microscopic polyangiitis;Respiratory failure,160642901,HO,,,,,,,,,160642901,1,HIV infection
16064291,160642911,1,I,,20190307,20190312,20190312,EXP,,AU-GLAXOSMITHKLINE-AU2019044390,GLAXOSMITHKLINE,GERHARDY B. AN ATYPICAL PNEUMONIA. RESPIROLOGY CASE REPORTS. 2019;7(3):ARTICLE NUMBER E00407. DOI: 10.1002/RCR2.407.,70,YR,,F,Y,,,20190312,,OT,AU,AU,EFAVIRENZ.,Acute kidney injury;Haemoglobin decreased;Microscopic polyangiitis;Respiratory failure,160642911,OT,,,,,,,,,160642911,1,HIV infection
16064392,160643921,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022461,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160643921,OT,,,,,,,,,160643921,1,HIV infection
16064397,160643971,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022464,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160643971,OT,,,,,,,,,160643971,1,HIV infection
16064422,160644221,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022497,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,SUSTIVA,Nervous system disorder;Treatment noncompliance;Virologic failure,160644221,OT,,,,,,,,,160644221,1,HIV infection
16064431,160644311,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022490,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160644311,OT,,,,,,,,,160644311,1,HIV infection
16064450,160644501,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022501,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160644501,OT,,,,,,,,,160644501,1,HIV infection
16064451,160644511,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022506,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160644511,OT,,,,,,,,,160644511,1,HIV infection
16064480,160644801,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022518,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160644801,OT,,,,,,,,,160644801,1,HIV infection
16064534,160645341,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022540,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645341,OT,,,,,,,,,160645341,1,HIV infection
16064554,160645541,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022563,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645541,OT,,,,,,,,,160645541,1,HIV infection
16064577,160645771,1,I,,20190307,20190312,20190312,EXP,,GB-MYLANLABS-2019M1022612,MYLAN,,,,A,,Y,,,20190312,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160645771,OT,,,,,,,,,160645771,1,HIV infection
16064738,160647382,2,F,20171006,20190311,20190312,20190318,EXP,,GB-MYLANLABS-2019M1022917,MYLAN,,43,YR,,F,Y,,,20190318,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,160647382,OT,,,160647382,1,20171006,20180205,,,160647382,1,HIV infection
16066602,160666021,1,I,20180503,20190227,20190313,20190313,EXP,,CN-GLAXOSMITHKLINE-CN2019038950,GLAXOSMITHKLINE,,59,YR,,M,Y,,,20190313,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160666021,OT,,,160666021,1,20180410,,,,160666021,1,HIV infection
16066624,160666241,1,I,20180503,20190227,20190313,20190313,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019038950,VIIV,,59,YR,,M,Y,,,20190313,,MD,CN,CN,EFAVIRENZ.,Dermatitis exfoliative,160666241,HO,,,160666241,1,20180410,,,,160666241,1,HIV infection
16066682,160666821,1,I,,20190311,20190313,20190313,EXP,,PT-GLAXOSMITHKLINE-PT2019043879,GLAXOSMITHKLINE,,43,YR,,M,Y,,,20190313,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160666821,OT,,,,,,,,,160666821,1,HIV test positive
16066684,160666841,1,I,,20190311,20190313,20190313,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2019043879,VIIV,,43,YR,,M,Y,,,20190313,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160666841,OT,,,,,,,,,160666841,1,HIV test positive
16066946,160669461,1,I,,20190307,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022809,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,SUSTIVA,Nervous system disorder;Virologic failure,160669461,OT,,,,,,,,,160669461,1,HIV infection
16066987,160669871,1,I,,20190307,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022905,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160669871,OT,,,,,,,,,160669871,1,HIV infection
16066988,160669881,1,I,,20190307,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022906,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Virologic failure,160669881,OT,,,,,,,,,160669881,1,HIV infection
16066993,160669931,1,I,,20190307,20190313,20190313,EXP,,GB-MYLANLABS-2019M1022909,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,SUSTIVA,Treatment noncompliance;Virologic failure,160669931,OT,,,,,,,,,160669931,1,HIV infection
16067745,160677451,1,I,,20190306,20190313,20190313,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-BI-010063",BOEHRINGER INGELHEIM,,60,YR,,M,Y,,,20190313,,OT,US,US,SUSTIVA,Drug resistance,160677451,OT,,,,,,,,,160677451,1,Product used for unknown indication
16067916,160679161,1,I,,20190308,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023099,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dermatitis allergic;Virologic failure,160679161,OT,,,,,,,,,160679161,1,HIV infection
16067918,160679181,1,I,,20190308,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023102,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Treatment noncompliance;Virologic failure,160679181,OT,,,,,,,,,160679181,1,HIV infection
16068024,160680241,1,I,,20190308,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023107,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160680241,OT,,,,,,,,,160680241,1,HIV infection
16068026,160680261,1,I,,20190308,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023109,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nervous system disorder;Virologic failure,160680261,OT,,,,,,,,,160680261,1,HIV infection
16068027,160680271,1,I,,20190308,20190313,20190313,EXP,,GB-MYLANLABS-2019M1023112,MYLAN,,,,A,,Y,,,20190313,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Treatment noncompliance;Virologic failure,160680271,OT,,,,,,,,,160680271,1,HIV infection
16068384,160683841,1,I,,20190306,20190313,20190313,EXP,,CA-MYLANLABS-2019M1023388,MYLAN,,,,,,Y,,,20190313,,OT,CA,CA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Foetal exposure during pregnancy;Ventricular septal defect,160683841,CA,,,,,,,,,160683841,1,Prophylaxis against HIV infection
16070460,160704601,1,I,20110825,20181206,20190314,20190314,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2018223044,VIIV,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35,YR,,F,Y,,,20190314,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704601,OT,,,,,,,,,160704601,1,HIV infection
16070467,160704671,1,I,20110825,20181206,20190314,20190314,EXP,,FR-GLAXOSMITHKLINE-FR2018223044,GLAXOSMITHKLINE,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018. DOI: 10.1111/CBDD.13378.",35,YR,,F,Y,,,20190314,,OT,FR,FR,EFAVIRENZ.,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160704671,OT,,,,,,,,,160704671,1,HIV infection
16073753,160737531,1,I,,20190308,20190314,20190314,EXP,,GB-MYLANLABS-2019M1023819,MYLAN,,,,A,,Y,,,20190314,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bone density abnormal;Glomerular filtration rate decreased;Nervous system disorder;Renal impairment,160737531,OT,,,,,,,,,160737531,1,Product used for unknown indication
16075222,160752221,1,I,,20190301,20190315,20190315,EXP,,FR-AUROBINDO-AUR-APL-2019-012832,AUROBINDO,,,,,,Y,,,20190315,,OT,FR,FR,EFAVIRENZ.,Pathogen resistance;Treatment failure,160752221,OT,,,,,,,,,160752221,1,HIV infection
16077788,160777881,1,I,2018,20181105,20190315,20190315,EXP,,UG-MYLANLABS-2018M1086621,MYLAN,,,,N,F,Y,3.07,KG,20190315,,OT,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Birth mark;Congenital umbilical hernia;Foetal exposure during pregnancy,160777881,CA,,,160777881,1,20180625,,,,160777881,1,HIV infection
16080755,160807551,1,I,,20190301,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013379,AUROBINDO,,,,,,Y,,,20190316,,OT,CA,CA,SUSTIVA,Anxiety,160807551,HO,,,,,,,,,160807551,1,Psychotic disorder
16080861,160808611,1,I,,20190301,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013750,AUROBINDO,,44,YR,,M,Y,,,20190316,,OT,CA,CA,SUSTIVA,Anxiety,160808611,OT,,,,,,,,,160808611,1,Psychotic disorder
16081150,160811501,1,I,,20190301,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,,,,,Y,,,20190316,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811501,OT,,,,,,,,,160811501,1,Product used for unknown indication
16081152,160811521,1,I,,20190301,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013775,AUROBINDO,,,,,,Y,,,20190316,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811521,HO,,,,,,,,,160811521,1,Product used for unknown indication
16081155,160811551,1,I,,20190301,20190316,20190316,EXP,,CA-AUROBINDO-AUR-APL-2019-013363,AUROBINDO,,,,,,Y,,,20190316,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,160811551,OT,,,,,,,,,160811551,1,HIV infection
16089254,160892541,1,I,,20190307,20190319,20190319,EXP,,GB-MYLANLABS-2019M1022798,MYLAN,,,,A,,Y,,,20190319,,MD,GB,GB,SUSTIVA,Virologic failure,160892541,OT,,,,,,,,,160892541,1,HIV infection
16091648,160916481,1,I,,20190306,20190319,20190319,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-023788,BRISTOL MYERS SQUIBB,,60,YR,,M,Y,,,20190319,,OT,US,US,SUSTIVA,Drug resistance,160916481,OT,,,,,,,,,160916481,1,Product used for unknown indication
16096424,160964241,1,I,,20190314,20190320,20190320,EXP,,CA-GILEAD-2019-0397265,GILEAD,,52,YR,A,M,Y,,,20190320,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,160964241,OT,,,,,,,,,160964241,1,HIV infection
16104926,161049261,1,I,,20190314,20190322,20190322,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019051107,VIIV,,52,YR,,M,Y,,,20190322,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161049261,OT,,,,,,,,,161049261,1,HIV infection
16104931,161049311,1,I,,20190314,20190322,20190322,EXP,,CA-GLAXOSMITHKLINE-CA2019051107,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20190322,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,161049311,OT,,,,,,,,,161049311,1,HIV infection
16106969,161069692,2,F,20180116,20190325,20190322,20190330,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK028179,GLAXOSMITHKLINE,,44,YR,,F,Y,41,KG,20190330,,MD,MZ,MZ,EFAVIRENZ.,Cervical vertebral fracture;Encephalitis;Spinal cord injury,161069692,HO,,,161069692,1,20170411,,,,161069692,1,HIV infection
16107024,161070242,2,F,20180116,20190325,20190322,20190330,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK028179,VIIV,,44,YR,,F,Y,41,KG,20190330,,MD,MZ,MZ,EFAVIRENZ.,Cervical vertebral fracture;Encephalitis;Spinal cord injury,161070242,OT,,,161070242,1,20170411,,,,161070242,1,HIV infection
16109205,161092051,1,I,20180202,20180305,20190323,20190323,EXP,,PHHY2018AM201640,NOVARTIS,,56,YR,,M,Y,,,20190323,,CN,US,AM,EFAVIRENZ.,Acute kidney injury;Anxiety;Hypersensitivity,161092051,OT,,,161092051,1,20170223,20170511,,,161092051,1,Pulmonary tuberculosis
16109810,161098101,1,I,,20190311,20190325,20190325,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-025141,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190325,,CN,US,US,SUSTIVA,Disability,161098101,DS,,,,,,,,,161098101,1,Product used for unknown indication
16109982,161099821,1,I,,20190312,20190325,20190325,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-025638,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20190325,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,161099821,HO,,,,,,,,,161099821,1,Product used for unknown indication
16110186,161101861,1,I,,20190312,20190325,20190325,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-025640,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20190325,,OT,CA,CA,SUSTIVA,Depression;Drug interaction,161101861,OT,,,,,,,,,161101861,1,Product used for unknown indication
16110301,161103012,2,F,20180122,20190318,20190325,20190328,EXP,,MZ-GLAXOSMITHKLINE-MZ2019GSK048950,GLAXOSMITHKLINE,,31,YR,,M,Y,40,KG,20190328,,MD,MZ,MZ,EFAVIRENZ.,Anaemia;Malnutrition,161103012,DE,,,161103012,1,20171124,20180228,,,161103012,1,HIV infection
16110356,161103562,2,F,20180122,20190318,20190325,20190328,EXP,,MZ-VIIV HEALTHCARE LIMITED-MZ2019GSK048950,VIIV,,31,YR,,M,Y,40,KG,20190328,,MD,MZ,MZ,EFAVIRENZ.,Anaemia;Malnutrition,161103562,DE,,,161103562,1,20171124,20180228,,,161103562,1,HIV infection
16115166,161151661,1,I,20190312,20190322,20190325,20190325,EXP,,US-VIIV HEALTHCARE LIMITED-US2019052604,VIIV,,56,YR,,M,Y,,,20190325,,CN,US,US,SUSTIVA,"Hallucination, auditory;Hallucination, visual;Insomnia;Nausea;Seizure;Vomiting",161151661,HO,,,161151661,1,20190311,20190318,,,161151661,1,HIV infection
16119495,161194951,1,I,201004,20190320,20190326,20190326,EXP,,LT-VIIV HEALTHCARE LIMITED-LT2019GSK052951,VIIV,,42,YR,,M,Y,,,20190326,,MD,LT,LT,EFAVIRENZ.,Drug resistance;Extrapulmonary tuberculosis;Lymph node tuberculosis;Viraemia,161194951,OT,,,161194951,1,20100324,201110,,,161194951,1,Product used for unknown indication
16119505,161195051,1,I,201004,20190320,20190326,20190326,EXP,,LT-GLAXOSMITHKLINE-LT2019GSK052951,GLAXOSMITHKLINE,,42,YR,,M,Y,,,20190326,,MD,LT,LT,EFAVIRENZ.,Drug resistance;Extrapulmonary tuberculosis;Lymph node tuberculosis;Viraemia,161195051,OT,,,161195051,1,20100324,201110,,,161195051,1,Product used for unknown indication
16127371,161273711,1,I,,20190315,20190328,20190328,EXP,,ML-CIPLA LTD.-2019ML01623,CIPLA,,,,,,Y,,,20190328,,OT,ML,ML,EFAVIRENZ.,Virologic failure,161273711,OT,,,,,,,,,161273711,1,HIV infection
16127383,161273831,1,I,,20190315,20190328,20190328,EXP,,ML-CIPLA LTD.-2019ML01621,CIPLA,,,,,,Y,,,20190328,,OT,ML,ML,EFAVIRENZ.,Virologic failure,161273831,OT,,,,,,,,,161273831,1,HIV infection
16128050,161280501,1,I,20190225,,20190225,20190225,DIR,,,FDA-CTU,,55,YR,,F,N,,,20190225,N,PH,US,US,SUSTIVA,Blood cholesterol increased;Insomnia,,,161280501,HP,161280501,1,201709,201902,,,,,
16134747,161347471,1,I,,20190315,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01616,CIPLA,,,,,,Y,,,20190329,,OT,ML,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161347471,OT,,,,,,,,,161347471,1,HIV infection
16134895,161348951,1,I,,20190321,20190329,20190329,EXP,,PT-MYLANLABS-2019M1027784,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NA?VE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY.. 2018;1-2",32,YR,,M,Y,,,20190329,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161348951,LT,,,,,,,,,161348951,1,Chronic hepatitis C
16134897,161348971,1,I,,20190321,20190329,20190329,EXP,,PT-MYLANLABS-2019M1027766,MYLAN,"SUZUKI F, HOSAKA T, SUZUKI Y, SEZAKI H, AKUTA N, FUJIYAMA S, ET AL.. LONG-TERM OUTCOME OF ENTECAVIR TREATMENT OF NUCLEOS (T) IDE ANALOGUE-NA?VE CHRONIC HEPATITIS B PATIENTS IN JAPAN.. JOURNAL OF GASTROENTEROLOGY. 2018;1-2",32,YR,,M,Y,,,20190329,,OT,PT,PT,EFAVIRENZ.,Drug-induced liver injury;Hepatic fibrosis,161348971,LT,,,,,,,,,161348971,1,HIV infection
16135471,161354711,1,I,,20190315,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01617,CIPLA,,,,,,Y,,,20190329,,OT,FR,ML,EFAVIRENZ.,Virologic failure,161354711,OT,,,,,,,,,161354711,1,HIV infection
16135486,161354861,1,I,,20190315,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01618,CIPLA,,,,,,Y,,,20190329,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161354861,OT,,,,,,,,,161354861,1,HIV infection WHO clinical stage II
16135514,161355141,1,I,,20190315,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01619,CIPLA,,,,,,Y,,,20190329,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161355141,OT,,,,,,,,,161355141,1,HIV infection
16135544,161355441,1,I,,20190315,20190329,20190329,EXP,,ML-CIPLA LTD.-2019ML01620,CIPLA,,,,,,Y,,,20190329,,OT,FR,ML,EFAVIRENZ.,Drug resistance;Virologic failure,161355441,OT,,,,,,,,,161355441,1,HIV infection
3990923,39909239,9,F,20030725,20190315,20030828,20190327,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-12363941,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,74,KG,20190327,,CN,FR,FR,SUSTIVA,Aggression;Ascites;Hepatic necrosis;Hepatitis A;Jaundice;Peritoneal haematoma;Somnolence;Vomiting,39909239,LT,,,39909239,1,20030412,20030728,,,39909239,1,HIV infection
6040321,60403212,2,F,20040206,20190125,20060508,20190201,EXP,,FR-GILEAD-2006-0009517,GILEAD,,35,YR,A,M,Y,63,KG,20190201,,MD,FR,FR,SUSTIVA,Abdominal pain upper;Amylase increased;Cholelithiasis;Hyperbilirubinaemia;Jaundice;Lipase increased;Pancreatitis acute;Pancreatitis chronic;Vomiting,60403212,HO,,,60403212,1,20030416,20050901,,,60403212,1,HIV infection
6054320,60543205,5,F,20060215,20190123,20060530,20190131,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13386032,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,54,KG,20190131,,OT,FR,FR,SUSTIVA,Chondropathy;Osteonecrosis,60543205,OT,,,60543205,1,20051117,,,,60543205,1,HIV infection
6056312,60563123,3,F,2006,20190125,20060601,20190201,EXP,,FR-GILEAD-2006-0009632,GILEAD,,50,YR,A,M,Y,54,KG,20190201,,OT,FR,FR,SUSTIVA,Chondropathy;Osteonecrosis,60563123,OT,,,60563123,1,20051117,,,,60563123,1,HIV infection
6075544,60755442,2,F,20051215,20190125,20060630,20190201,EXP,,FR-GILEAD-2006-0009794,GILEAD,,51,YR,A,M,Y,58,KG,20190201,,MD,FR,FR,SUSTIVA,Gynaecomastia,60755442,HO,,,60755442,1,20050613,20060514,,,60755442,1,HIV infection
6078567,60785672,2,F,,20190125,20060707,20190201,EXP,,FR-GILEAD-2006-0009823,GILEAD,,50,YR,A,F,Y,45,KG,20190201,,MD,FR,FR,SUSTIVA,Hyperphosphaturia;Osteomalacia;Osteoporosis;Renal tubular dysfunction,60785672,DS,,,60785672,1,20021008,20060413,,,60785672,1,HIV infection
6079477,60794772,2,F,200606,20190123,20060710,20190205,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13428768,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20190205,,OT,FR,FR,SUSTIVA,Acute kidney injury;Cholelithiasis;Hepatomegaly;Pyelonephritis acute,60794772,OT,,,60794772,1,,20060607,,,60794772,1,HIV infection
6089495,60894952,2,F,20041201,20190123,20060724,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13445606,BRISTOL MYERS SQUIBB,,57,YR,,M,Y,49,KG,20190201,,OT,FR,FR,SUSTIVA,Blood creatinine increased;Fanconi syndrome;Hypophosphataemia,60894952,OT,,,60894952,1,20030901,20060408,,,60894952,1,HIV infection
6118986,61189862,2,F,20060415,20190125,20060830,20190201,EXP,,FR-GILEAD-2006-0010082,GILEAD,,52,YR,A,M,Y,64,KG,20190201,,MD,FR,FR,SUSTIVA,Cholestasis;Hyperlipidaemia;Hypertension;Renal infarct;Splenic infarction,61189862,LT,,,61189862,1,20040719,,,,61189862,1,Acquired immunodeficiency syndrome
6158885,61588852,2,F,20060710,20190125,20061031,20190205,EXP,,FR-GILEAD-2006-0010537,GILEAD,,41,YR,A,M,Y,55,KG,20190205,,MD,FR,FR,SUSTIVA,Onychomadesis;Pruritus;Rash;Stevens-Johnson syndrome,61588852,HO,,,61588852,1,20060615,20060728,,,61588852,1,HIV infection
6243336,62433362,2,F,20070106,20190125,20070222,20190206,EXP,,FR-GILEAD-2007-0011292,GILEAD,,47,YR,A,M,Y,,,20190206,,MD,FR,FR,SUSTIVA,Drug reaction with eosinophilia and systemic symptoms;Eosinophilia;Eyelid oedema;Face oedema;Hepatitis;Lip oedema;Oral disorder;Oral fungal infection;Parapsoriasis;Rash papular;Seborrhoeic dermatitis,62433362,HO,,,62433362,1,20070103,20070108,,,62433362,1,Product used for unknown indication
6264473,62644735,5,F,20061129,20190215,20070319,20190225,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13714431,BRISTOL MYERS SQUIBB,,1,DY,,F,Y,,,20190225,,OT,FR,FR,SUSTIVA,Exomphalos;Foetal exposure during pregnancy,62644735,DS,,,62644735,1,,20061019,,,62644735,1,Product used for unknown indication
6870587,68705873,3,F,20060602,20190131,20081231,20190212,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14457303,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20190212,,CN,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,68705873,OT,,,68705873,2,20060602,20070522,,,68705873,1,HIV infection
7111460,71114605,5,F,20090930,20190123,20090911,20190201,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-14642565,BRISTOL MYERS SQUIBB,,19,YR,,F,Y,,,20190201,,CN,FR,FR,SUSTIVA,Caesarean section;Drug interaction;Maternal exposure during pregnancy;Normal newborn;Pregnancy on contraceptive,71114605,OT,,,71114605,1,20080724,,,,71114605,1,HIV infection
7152253,71522539,9,F,,20190317,20091019,20190322,EXP,,CA-PFIZER INC-2009279889,PFIZER,"PFEFFER, G.. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY. 2009;73 (1):71-72",52,YR,,M,Y,,,20190322,,OT,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,71522539,OT,,,,,,,,,71522539,1,HIV infection
7820530,78205302,2,F,,20190204,20110221,20190212,EXP,,GR-GILEAD-2011-0036333,GILEAD,,74,YR,E,M,Y,,,20190212,,MD,GR,GR,EFAVIRENZ.,Acute kidney injury;Drug interaction;Lactic acidosis,78205302,OT,,,,,,,,,78205302,1,HIV infection
8019802,80198024,4,F,,20190205,20110705,20190214,EXP,,GR-BRISTOL-MYERS SQUIBB COMPANY-15871460,BRISTOL MYERS SQUIBB,,74,YR,,M,Y,,,20190214,,MD,GR,GR,EFAVIRENZ.,Acute kidney injury;Lactic acidosis,80198024,HO,,,,,,,,,80198024,1,Diabetes mellitus
